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Summary
Polybrominated diphenylethers (PBDEs) are widely used as additive flame retardants in
many different plastic materials and textiles at concentrations ranging from 5% to 30%. As
they are not covalently bound, but admixed to polymers, they can be released into the
environment, where they bioaccumulate as a result of their lipophilic characteristics.
PBDEs have been detected in various biotic samples such as birds, eels, seals, whales,
and also in human blood, adipose tissue, and breast milk. The relevance of PBDEs as
environmental contaminants has been realized a few years ago, when it was
demonstrated that concentrations in Swedish human milk have markedly increased over
the last two decades.
Knowledge on PBDE toxicity is quite limited. The most sensitive end points of PBDEs in
vivo so far known are effects on thyroid function, observed as induction of thyroid
hyperplasia and alteration of thyroid hormone production in rats and mice; PBDEs were
also found to have neurotoxic effects. Major data gaps include their effects on
development, reproduction, and carcinogenicity.
The aim of our study was to provide information on the effects of PBDEs on development
of a mammalian species, the rat, with special emphasis on reproductive organs. The basic
hypothesis was that PBDEs, which bear some resemblance to PCBs, might interfere with
the endocrine system, in the manner of an endocrine disruptor.
The congener selected was PBDE 99, (2,2’,4.4’,5- pentabromo-diphenylether), one of the
congeners found in the biosphere, and present in human milk. In preliminary experiments,
PBDE 99 had been found to be neurotoxic in newborn mice.
PBDE 99 was injected subcutaneosly to time-pregnant Long Evans rats from gestational
day 10 (GD 10) to GD 18, at doses of 1 mg/kg and 10 mg/kg (9 injections). Additional
groups of time-pregnant dams were treated with Aroclor 1254, an industrial PCB mixture,
(10 mg/kg and 30 mg/kg), or with vehicle (olive oil). Aroclor 1254 was used as positive
control, with the aim to compare PBDE effects with those of PCBs, which are well
documented.
The rat offspring (F1 generation) were monitored from birth to adulthood. Survival rate and
body weight were not affected by PBDE 99 indicating absence of general toxicity at the
doses used. The onset of puberty was delayed in females (vaginal opening) and advanced
in males (preputial separation). Data from organ weights of adult offspring indicate
changes in ventral and dorsal prostate (1 and 10 mg/kg PBDE 99, respectively),
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epididymis (both doses) and in ovaries (10 mg/kg PBDE 99). Aroclor 1254 delayed the
onset of puberty in females at 30 mg/kg, anda affected the weight of epididymis, seminal
vesicles, uterus, and ovaries at the dose of 10mg/kg. Animals exposed to 30 mg/kg of
Aroclor 1254 exhibited a marked reduction of early postnatal survival rate and rarely
reached adulthood. Females appeared to be more sensitive.
In order to obtain information on possible longterm effects at the molecular level, mRNA
levels of the estrogen target genes insulin-like growth factor-I (IGF-I), estrogen receptor 
(ER ) and ER, progesterone receptor (PR), and androgen receptor (AR) was performed
in dorsal and ventral prostate and in uterus of adult offspring. mRNA levels were quantified
by Real Time-PCR, with cyclophilin as reference.
In ventral prostate of adult offspring, PBDE 99 given at 1 mg/kg significantly down-
regulated IGF-I, AR, and ER mRNA levels; the higher dose (10 mg/kg) down-regulated all
the genes studied. Aroclor 1254 decreased IGF-I, AR, and ER mRNA levels at a dose of
10 mg/kg.
In dorsal prostate, prenatal administration of PBDE 99 resulted in a different effect
spectrum. Adult offspring exhibited increased levels of AR mRNA (both PBDE 99 doses)
and ERα mRNA (10 mg/kg), but reduced ER mRNA (both doses), while the level of IGF-I
mRNA was unchanged. Aroclor 1254 increased IGF-I mRNA levels.
In uterus of adult offspring, developmental exposure to the low dose of PBDE 99 resulted
in down-regulation of PR mRNA and up-regulation of ER mRNA. Exposure to the higher
dose decreased PR and ER mRNAs. Aroclor 1254 decreased ER mRNA levels.
Additional experiments were conducted in order to assess the responsiveness of
estrogen-regulated genes to estrogen. Adult male and female offspring exposed to PBDE
99 during development were gonadectomized in order to reduce and stabilize endogenous
sex hormone levels, and injected with estradiol subcutaneously 2 weeks later. Animals
were investigated 6 hours after estradiol injection.
The analysis of acute changes in mRNA levels (6 hours) revealed sex- and tissue-specific
alterations in the sensitivity of estrogen-regulated genes to estradiol in adult offspring
following exposure to PBDE 99 during development. The acute induction of IGF-I mRNA
by estradiol was reduced in ventral prostate and uterus. Uterus further exhibited enhanced
responses of PR mRNA (induction) and ER mRNA (suppression). These data indicate
changes in the regulation of the respective genes. The changes in steady state mRNA
levels and in response to estradiol could have resulted from actions of PBDE 99 during
early ontogeny or at later stages, or from a combination of both.
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In conclusion our results indicate that prenatal PBDE 99 exposure can affect the
development of the rat gonadal axis, with changes in reproductive organ weights and in
estrogen target gene expression. The action corresponds to effects of endocrine
disruptors. The effect patterns differ in part from those of the PCB mixture, Aroclor 1254,
indicating that the two groups of chemicals deserve separate consideration.
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Zusammenfassung
Polybromierte Diphenyläther (PBDE) finden breite Anwendung als Flammschutzmittel in
Plastikwaren und Textilien in Konzentrationen von 5 bis 30%. Da sie nicht kovalent
gebunden, sondern dem Polymer zugemischt werden, können sie relativ leicht aus dem
Material herausdiffundieren und in die Umwelt gelangen, wo sie dank ihren lipophilen
Eigenschaften bioakkumulieren. PBDE-Kongenere wurden in verschiedensten biotischen
Proben gefunden; z.B. in Vögeln, Aalen, Robben, Walen und in menschlichem Blut,
Fettgewebe und Humanmilch. Die Relevanz der PBDE als Umweltkontaminantien wurde
erst vor einigen Jahren erkannt, als bekannt wurde, dass die Konzentrationen in
Humanmilch schwedischer Frauen in den letzten zwei Jahrzehnten exponentiell gestiegen
sind.
Über die Toxizität der PBDE ist wenig bekannt. PBDE können in vivo die
Schilddrüsenfunktion beeinflussen, es wurden Schilddrüsenhyperplasie und Veränderung
der Schilddrüsenhormonkonzentrationen bei Ratten und Mäusen beobachtet. PBDE
können auch neurotoxisch wirken. Was fehlt, sind Daten über Entwicklung, Reproduktion
und Kanzerogenität.
Das Ziel unserer Untersuchungen war, mehr über mögliche Wirkungen von PBDE auf die
Entwicklung einer Säugetierspezies, der Ratte, speziell über die Entwicklung der
Reproduktionsorgane, zu erfahren. Die Hypothese war, dass PBDE, die Ähnlichkeiten mit
PCB besitzen, möglicherweise wie ein endokriner Disruptor mit der Entwicklung
endokriner Systeme interagieren könnten.
Für die Untersuchungen wurde das Kongener PBDE 99, (2,2’,4.4’,5-Pentabromo-
diphenyläther) ausgewählt. PBDE 99 wurde in der Biosphäre, z.B. in Humanmilch,
nachgewiesen, und hatte sich in präliminären Experimenten an neugeborenen Mäusen als
neurotoxisch erwiesen. PBDE 99 wurde trächtigen Long Evans Ratten mit zeitlich
kontrollierter Begattung in Dosierungen von 1 mg/kg und 10 mg/kg subkutan injiziert, und
zwar vom Schwangerschaftstag 10 bis 18 (9 Injektionen). Eine zusätzliche Gruppe
trächtiger Rattenweibchen wurde in analoger Weise mit Aroclor 1254, einer industriellen
PCB-Mischung (10 mg/kg oder 30 mg/kg), behandelt. Kontrollen erhielten das Vehikel
(Olivenöl). Aroclor 1254 diente als Positivkontrolle, mit dem Ziel, PBDE-Effekte mit
denjenigen von PCB zu vergleichen. Letztere sind sehr gut dokumentiert.
Die postnatale Entwicklung der Nachkommen (F1-Generation) wurde von Geburt bis ins
erwachsene Alter beobachtet. Überlebensrate und Körpergewicht wurden durch PBDE 99
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nicht beeinflusst, was anzeigt, dass PBDE 99 in den verwendeten Dosierungen keine
allgemein toxischen Effekte ausübte. Der Beginn der Pubertät war bei weiblichen, PBDE
99-exponierten Jungtieren verzögert (Vaginalöffnung), bei Männchen vorverschoben
(Ablösung des Präputiums). Änderungen des Organgewichts zeigten bei adulten
Nachkommen ventrale und dorsale Prostata (1 bzw. 10 mg/kg PBDE 99), Epididymis
(beide Dosisgruppen) und Ovarien (10 mg/kg PBDE 99). Aroclor 1254 verzögerte den
Pubertätseintritt bei Weibchen (30 mg/kg) und beeinflusste die Organgewichte von
Nebenhoden, Samenblasen, Uterus und Ovarien adulter Nachkommen in der
Konzentration von 10 mg/kg. Jungtiere der Dosisgruppe 30 mg/kg Aroclor 1254 zeigten
eine markante Reduktion der postnatalen Überlebensrate und erreichten kaum das
Erwachsenenalter. Weibchen schienen empfindlicher zu sein.
Um Aufschluss über Langzeiteffekte auf molekularer Ebene zu gewinnen, wurden die
mRNA-Konzentrationen der Estrogen-Zielgene Insulin-like Growth Factor-I (IGF-I),
Estrogen-Rezeptor  (ER) und ER, Progesteron-Rezeptor (PR) und Androgen-Rezeptor
(AR) in der dorsalen und ventralen Prostata und im Uterus adulter Jungtiere mit Hilfe der
Real Time PCR Methode bestimmt. Cyclophilin diente als Referenzgen.
In der ventralen Prostata adulter Jungtiere senkte PBDE 99 in einer Dosis von 1 mg/kg die
mRNA-Konzentrationen von IGF-I, AR, und ER, während bei der höheren Dosis (10
mg/kg) alle untersuchten Gene herunterreguliert wurden. Aroclor 1254 (10 mg/kg)
reduzierte IGF-1, AR, und ER mRNA. Die dorsale Prostata zeigte ein anderes
Effektspektrum. Pränatale Verabreichung von PBDE 99 erhöhte bei adulten Jungtieren die
Konzentrationen von AR mRNA (beide Dosisgruppen) und ERα mRNA (10 mg/kg),
reduzierte ER mRNA (beide Dosierungen), hatte aber keine Wirkung auf die IGF-I mRNA
Konzentration.
Im Uterus fand sich unter der niedrigen PBDE 99-Exposition eine Reduktion von PR
mRNA und ein Anstieg von ER mRNA. Bei der höheren Dosis wurden die
Konzentrationen von PR mRNA und ER mRNA herunterreguliert. Aroclor 1254 reduzierte
die Konzentration von ER mRNA.
Zusätzliche Experimente wurden ausgeführt, um die Empfindlichkeit der Estrogen-
regulierten Gene auf Estrogen zu untersuchen. Ratten beiderlei Geschlechts, die während
der Entwicklung PBDE 99-exponiert waren, wurden im jung-adulten Alter gonadektomiert,
zur Reduktion und Stabilisierung der Konzentrationen der endogenen
Geschlechtshormone. Zwei Wochen später wurde den Tieren Estradiol subkutan injiziert.
Sechs Stunden danach wurden sie untersucht.
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Die Analyse zeigte geschlechts- und gewebeabhängige Veränderungen der akuten
Reaktion Estrogen-regulierter Gene auf Estradiol in ventraler Prostata und Uterus. Die
akute Induktion von IGF-1 mRNA durch Estradiol war in ventraler Prostata und Uterus
herabgesetzt. Im Uterus fand sich ausserdem eine verstärkte Induktion von PR mRNA und
eine verstärkte Suppression von ER mRNA. Dies spricht für eine veränderte Regulation
dieser Gene. Die Änderungen der mRNA-Konzentrationen im stationären Zustand und die
veränderte Sensitivität für E2 könnten durch den Einfluss von PBDE 99 auf die frühe
Ontogenese und/oder durch Wirkungen in der späteren postnatalen Entwicklung
verursacht worden sein.
Zusammenfassend zeigen unsere Resultate, dass PBDE 99-Exposition die Entwicklung
des Reproduktionstraktes männlicher und weiblicher Ratten auf der Organebene und auf
molekularer Ebene beeinflussen kann. Die Wirkung entspricht jener von endokrinen
Disruptoren. Das Effektmuster von PBDE 99 weicht zum Teil von jenem des PCB-
Gemisches, Aroclor 1254, ab, was eine getrennte Betrachtung der zwei
Chemikaliengruppen nahelegt.
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1. Introduction
1.1 General Introduction
During recent years, chemicals able to interfere with endocrine systems of humans and
animals, have received increasing attention. So far most of the literature deals with
xenoestrogens, chemicals that interfere with the female sexual hormone estrogen.
The effects of the xenoestrogens were first discovered in rivers and below influxes of
sewage treatment plants, where an increased number of fish with defects in liver, kidneys
and reproductive organs were observed (BUWAL, 1999). In addition males produced
increased amounts of the female egg-yolk protein vitellogenin (Munkittrick et al., 1991;
Sumpter and Jobling 1993). Synthesis of this protein is induced by estrogens or “estrogen
like” substances in water.
In many animal species like marine mammals a decrease in fertility is seen (Colborn and
Smolen, 1996). Highly lipophilic chemicals bio-accumulate in living organisms and are
stored in adipose tissues like in the blubber of marine mammals. Such chemicals are
supposed to contribute to reproductive dysfunction.
There is increasing evidence that humans can also be affected by exposure to
contaminants in the food chain or by accidents. The high discharge of TCDD (Dioxin) in
the Seveso accident in 1976 led to an altered sex ratio (decrease from 51% to 35% in
births of boys). High TCDD contamination with serum concentrations of 15 to 20 ng ppt
TCDD of the fathers at peripubertal age could be correlated with the changes in sex ratio
of their children that normalized in 1985, when TCDD contamination had decreased
(Mocarelli et al., 2000).
Another highly discussed topic is the earlier onset of puberty in girls. It is known from
animal studies, that exposure to xenoestrogens can reduce the age of onset of puberty in
females, while exposure to compounds that interfere with androgens delay puberty in
males (Howdeshell et al., 1999; Gray et al., 1999).
Chemicals, such as diethylstilbestrol (DES), bisphenol A (BPA), and mixtures of
polychlorinated biphenyls (PCB) (Eroschenco et al., Katsuda et al., 2000, Vreugdenhil et
al., 2002) may have long-term effects on human health due to their estrogenic activity.
After fetal exposure, DES and BPA increased androgen receptor (AR) binding activity of
the prostate in adult rats at low doses (from 100 ng/kg/day to 50g/kg/day) and altered
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prostate and epididymis size (vom Saal et al., 1998; Atanassova et al., 2000; Declos et al.,
2001; Stoker et al., 1999).
From this point of view, it is evident that there is a need to investigate more closely the
effects of several compounds on humans and animals.
1.2 The Flame Retardants
The idea of flame retardant material dates back to about 450 BC, when the Egyptians
used alum to reduce the flammability of wood. The Romans (about 200 BC) used a
mixture of alum and vinegar to reduce the combustibility of wood. Today, there are more
than 175 chemicals classified as flame retardants. The four major groups are inorganic,
halogenated organic, organophosphorus and nitrogen-based flame retardants.
Advances in polymer science over the past 50 years has led to the introduction of a large
number of polymers with different properties and applications. As a result, we are
surrounded by a wide variety of polymers in clothing and furniture, vehicles and
computers. In fact modern cars contain in excess of 100 kg of various polymers. Most of
these polymers are petroleum-based and hence are flammable. In order to meet fire safety
regulations, flame retardants are applied to combustible materials such as plastics, wood,
paper, and textiles. Flame retardants are materials added or applied to a material to
increase the fire resistance of that product. With the increasing usage of polymeric
materials in construction, electronic and computer equipment, global market demand
continues to grow substantially (Alae et al., 2003).
The Brominated Flame Retardants
Brominated flame retardants (BFRs) are used in a variety of consumer products and
several of those are produced in large quantities. They are produced via direct bromination
of organic molecules or via addition of bromine or alkenes.
BFRs are divided into three subgroups depending on the mode of incorporation of these
compounds into the polymers: brominated monomers, reactive and additive. A brominated
monomer such as brominated styrene or brominated butadiene is used in the production of
brominated polymers, which are then blended or introduced into the feed prior to
polymerisation, resulting in a polymer containing both brominated and non-brominated
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monomers. Reactive flame retardants, such as tetrabromobisphenol A, are chemically
bonded into the plastics. Additive flame retardants, which include Polybrominated diphenyl
ethers (PBDEs) are simply blended with polymers, and are more likely to leach out of the
products (Hutzinger et al., 1987).
Polybrominated Diphenylethers
Polybrominated diphenyl ethers (PBDEs) are additive flame retardants and the next
highest production group of BFRs currently in use. They are used in plastic (concentration
5-30%) and textile coatings. The general chemical formula is C12H(9-0)Br(1-10)O with the
sum of H and Br atoms always equal to 10. They are molecules containing 10 hydrogen
atoms, any of which can be exchanged with bromine, resulting in 209 possible congeners
and divided into 10 congener groups. The structure of PBDEs is similar to that of PCBs,
hence its nomenclature is also used for PBDEs.
PBDEs are produced at three different degrees of bromination, i.e. Penta-BDE, Octa-BDE
and Deca-BDE and classified according to their average bromine content. Commercial
PBDEs are quite resistant to physical, chemical, and biological degradation. The boiling
point of PBDEs is between 310 and 425°C and their vapor pressure is low at room
temperature. PBDEs are lipophilic, and their solubility in water is low, especially for the
higher brominated compounds. The global production is about 40,000 tons per year
(Darnerud et al., 2001).
The Penta-brominated Diphenylethers
The two major congeners present in the commercial Penta-BDE are: 2,2’,4,4’-
tetrabromodiphenyl ether (BDE-47) and 2,2’,4,4’,5-pentabromodiphenyl ether (BDE-99).
The formation of these two congeners is due to the presence of other precursors, the
congener mostly favored is BDE-47 and its continued bromination yields mainly the BDE-
99 and to a lesser extent 2,2’,4,4’,6-penta-BDE (BDE-100). The percentages of BDE-99
and BDE-100 in commercial mixtures are 35% and 6.8%, respectively. The favored
formation of BDE-99 might result from the ortho/para directing property of the bromine
atoms in BDE-47 and/or steric hindrance.
Penta-BDE formulation is a viscous liquid, which contains 70% bromine by weight,
consists of 41-42% tetra-BDEs (mainly BDE-47), 44-45% Penta-BDEs (predominantly
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BDE-99 and to a lesser extent BDE-100). The formulation of Penta-BDE contains the three
predominant congeners (BDE-47, BDE-99 and BDE-100), which are also found in
biological matrices including human tissue (de Wit, 2002).
Figure 1.1: The Penta-brominated diphenyl
ethers general formula.
.
Because of the widespread production and use of PBDEs, their high affinity to particles,
and their lipophilic characteristics, several PBDE congeners bio-concentrate and bio-
accumulate in the environment in a manner similar to the structurally related
polychlorinated biphenyls (PCBs) (Pijnenburg AMCM, et al., 1995).
PBDEs have been detected in various biotic samples such as birds, seals, whales, and
even in human blood, adipose tissue, and breast milk (de Boer J. et al.,1998; Stanley JS.
et al., 1991).
The relevance of PBDEs as environmental contaminants has been demonstrated by their
accumulation in human breast milk, where concentrations in Swedish women have
increased over the last 2 decades from 0.07 ng/g lipid weight in 1972 to 4.02 ng/g lipid
weight in 1998 (fig. 1.2) (Meroyntè D. et al.,1999).
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Although PCB concentrations in wildlife are still higher than PBDE concentrations, the
former are declining over the same time period, while PBDE levels are rising.
The most sensitive end points of PBDE toxicity in vivo so far include effects on thyroid
function, observed as induction of thyroid hyperplasia and alteration of thyroid hormone
production (i.e., lowering of free and total thyroxine (T4) concentrations) in rats and mice
(Darnerud PO. Et al., 1996; Fowels JR. et al., 1996).
Consistent with these findings is the recent observation that several pure PBDE congeners
were able to displace T4 from transthyretin (TTR; a plasma transport protein of thyroid
hormones) in vitro, after metabolic conversion to hitherto unidentified metabolites (Meerts
et al., 2000). These phenomena have also been observed for
other organhalogen compounds with similar structure: the PCBs and their hydroxylated
metabolites (Brucker-Davis 1998).
Another property that PBDEs share with PCBs and the polybrominated biphenyls (PBBs)
is the dioxin-like, Ah receptor-mediated induction of cytochrome P450 1A1 and 1A2 in vitro
(Brouwer A. et al., 1998) and in vivo (Hamberg A. et al., 1998).
Some studies have indicated that hydroxylated PBDEs are of potential environmental
importance. In liver microsomes of rats, several PBDE congeners were bio-transformed to
metabolites (Meerts et al., 2000).
Figure 1.2: PBDEs
increase in Swedish
human breast milk
over almost 2 decades:
from 1972 to 1998
(Meynrote, 1999).
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PBDEs: International and National Legislation and Restrictions
The need for restrictions on certain PBDEs in different types of plastics and textiles is
currently being discussed within the EU. Consequently, the use of certain brominated
flame retardants (PBB and tris(2,3-dibromopropyl)phosphate) in textiles has already been
banned. A document of the Organization for Economic Co-operation and Development
(OECD) document proposes precautions for each type of PBDEs. These include
recommendations to stop the use of certain compounds (mainly tetra- and penta-BDEs),
as well as to limit occupational exposure (OECD, 1994). Also the Paris Commission for the
Prevention of Marine Pollution is working toward restricting and phasing out PBDEs and
PBBs.
An example of a national restriction is the Swedish government’s intention to ban PDEs
and PBBs in products sold on the Swedish market (The Swedish National Chemicals
Inspectorate, 1999)
1.3. PCBs
Polychlorinated biphenyls (PCBs) consist of 12 carbon atoms, forming two aromatic phenyl
rings attached to one another through a carbon-carbon bridge, and 10 atoms that can be
either hydrogens or chlorines (fig. 3).
Cl Cl
Figure 1.3: Structure of PCB.
Chlorine increases the stability and decreases flammability of these compounds.
All PCBs are lipophilic and pratically insoluble in water. Lipophilicity increases by
increasing rate of chlorination. Their boiling point varies from 300 to 400°C. They resist
high temperatures and oxidising conditions.
Their electrical conductivity is very low which made them suitable cooling liquids for
electrical equipment and they have been used as insulating materials in electrical
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equipment, as plasticizers and for other industrial purposes (lubricants, cutting oils,
adhesives and etc.).
They were manufactured from 1930 to 1970s or 1980s (varying in different countries), and
the total production was in excess of a million tonnes. They have spread to the
environment in accidents (such as transformer fires or leaks), from volatilisation of waste
landfills and incineration of mixed municipal waste. The major source of human exposure
was food, expecially fatty food.
Effects on humans were observed as liver enlargement and immunological problems.
(Fowels et al., 1994).
Trade names for PCBs include the following: Apirolio, Aroclor, Clophen, Fenchlor,
Kanechlor, Phenochlor, Pyralene, Pyranol, Pyroclor, Santotherm Fr, and Sovol.
Sometimes the trade name indicates the degree of chlorination, e.g. Aroclor 1254 contains
54% of chlorine, 12 indicates the number of carbon atoms.
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1.4 Endocrine Disruptors
An endocrine disruptor (EDC) is an exogenous substance or mixture that alters function(s)
of the endocrine system and consequently can cause adverse health effects in an intact
organism, or its progeny, or in (sub)populations.
The last decades have witnessed growing scientific concerns and public debate over the
potential adverse effects that may result from exposure to a group of chemicals that have
the potential to alter the normal functioning of the endocrine system in wildlife and
humans.
Concerns regarding exposure to these EDCs are due primarily to:
1. Adverse effects observed in certain wildlife, fish, and ecosystems.
2. The increased incidence of certain endocrine-related human diseases.
3. Endocrine disruption resulting from exposure to certain environmental
chemicals observed in laboratory animals.
These concerns have stimulated many national governments, international organizations,
scientific societies, the chemical industry, and public interest groups to establish research
programs.
Endocrine Mechanisms of Action
Research has clearly shown that EDCs can act at multiple sites via multiple mechanisms
of action. Receptor-mediated mechanisms have received the most attention, but other
mechanisms (e.g., hormone synthesis, transport, and metabolism) have been shown to be
equally important. For most associations reported between exposure to EDCs and a
variety of biologic outcomes, the mechanism(s) of action are poorly understood. This
makes it difficult to distinguish between direct and indirect effects and primary versus
secondary effects of exposure to EDCs.
It also indicates that considerable caution is necessary in extrapolating from in vitro data to
in vivo effects, in predicting effects from limited in vivo data, and in extrapolating from
experimental data to the human situation.
Despite an overall lack of knowledge of mechanisms of action of EDCs, there are several
examples where the mechanism of action is clearly related to direct perturbations of
endocrine function and ultimately to adverse in vivo effects.
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Important aspects to be considered are:
• Exposure to EDCs during the period when “programming” of endocrine
system is in progress may result in a permanent change of function or sensitivity to
stimulation/inhibitory signals.
• Exposure in adulthood may be compensated for by normal homeostatic
mechanisms and may therefore not result in any significant or detectable effects.
• Exposure to the same level of an endocrine signal during different seasons
may produce different effects.
• Because of cross talk between different components of the endocrine
systems, effects may occur unpredictably in endocrine target tissues other than the
system predicted to be affected.
Today there is little knowledge of the relationship between molecular events and potential
adverse health outcomes.
Dose-Response Relationships
The issue of dose-response relationships is perhaps the most controversial issue
regarding EDCs. One of the reasons is that EDCs often act by mimicking or antagonizing
the action of naturally occurring hormones. These hormones (often more potent than
exogenous EDCs) are present at physiologically functional concentrations, so the dose-
response considerations for EDCs are often different from other environmental chemicals,
which are not acting directly on the endocrine system. Reports of low-dose effects of
EDCs are highly controversial and the subject of intense research. The existence of low-
dose effects has been confirmed by an international panel (Endocrine Disruptors Low
Dose Peer Review, 2001). Dose-response relationships are likely to vary for different
chemicals and endocrine mechanisms. Timing of exposure is absolutely critical to the
understanding of dose-response relationships for EDCs. This is true for both wildlife and
humans and for cancer as well for developmental, reproductive, immunological, and
neurobiological effects.
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Effects in Wildlife
Several field and laboratory studies have shown that exposure to certain EDCs has
adverse effects in some wildlife species and populations. These effects vary from subtle
changes in the physiology and sexual behaviour of species to permanently altered sexual
differentiation. Most of the data originate from Europe and North America. Aquatic species
(at the top of food chain) have been most frequently studied, but effects have also been
observed in terrestrial species. Some adverse effects observed in certain species are likely
to be endocrine mediated, but in most cases, the casual link between exposure and
endocrine disruption is unclear. Examples of cases observed:
 Mammals: exposure to organochlorines (PCBs, DDE) has been shown to
adversely impact the reproductive and immune function in Baltic seals, resulting in
marked population declines (Reijnder PJH, 1980; 1986; and 1990).
 Birds: eggshell thinning and altered gonadal development have been
observed in birds of prey exposed to DDT, resulting in severe population declines.
A syndrome of embryonic abnormalities has been observed in fish-eating birds and
can be directly related to PCB exposure (Fry DM et al., 1987; Gilbertson M. et al.,
1991; NcArthur MLB et al.,1983).
 Reptiles: a pesticide spill in Lake Apopka provides a well-documented
example of potential EDC effects on population decline in alligators. Several
hypotheses have been proposed to explain that organochlorine contaminants
induced endocrine disruption (Guillette LJ et al., 1994 and 1999a).
 Amphibians: population declines has been observed in both pristine and
polluted habitats worldwide (Vos JG et al., 2000).
 Fish: there is extensive evidence that chemical constituents present in pulp
and paper mill effluent and sewage treatment effluents can affect reproductive
endocrine function and contribute to alteration in reproductive development (Kime
et al., 1999; Mellanen et al., 1999).
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Human Health Effects
It is difficult to compare and integrate results from diverse human studies, because data
are often collected at different time periods, using different experimental designs and at
different exposure conditions (Farrow S., 1994). Often exposure data are completely
lacking. Of particular concern is the lack of exposure data during critical periods of
development that influence later functioning in adult life (Berman NG., 1996). Furthermore,
the concentrations and potencies of endogenous hormones and phytoestrogens are
generally higher than those of exogenous chemicals, but the situation changes with the life
cycle. For example, endogenous estrogen-concentrations are very low in embryos and
fetuses. Also, the kinetics (transport, tissue distribution, metabolism) differ greatly between
endogenous hormones, phytoestrogens and industrial chemicals. Despite these difficulties
in interpretation, exposure to EDCs has been suggested to play a role in adverse health
outcomes, and concerns remain.
Examples illustrating these concerns:
 Reproductive effects: a number of studies have reported a decline in human
sperm quality in several countries, but there are no firm data that directly addressed
the possible cause and effect relationship between declining sperm quality and
exposure to EDCs (Nelson et al., 1974; Irvine et al., 1996) mainly because of the
lack of data on pre- and postnatal exposure levels. Declining sex ratios (fewer
males) have been recorded in a number of regions and countries. There is also
evidence that unidentified external influences are associated with such changes,
but the mechanisms are unknown (Bush B. et al., 1986). This is supported by the
data of the Seveso accident mentioned above (Mocarelli et al., 2000).
 Endometriosis: exposure to certain EDCs has been reported to be associated
with endometriosis but, the studies remain equivocal (Guarnaccia & Olive, 1998;
Boyd et al., 1995).
 Neural function: alteration in sexually dimorphic play behaviour have been
linked to prenatal PCB exposure (Vrengdemhil et al., 2002).
 Immune function: exposure to environmental chemicals has shown to alter
immune function in humans and animals. However, it is not clear whether such
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impaired function is due to endocrine-mediated mechanisms (Chen RC. Et al.,
1985).
 Cancer: increases in the incidence of certain cancers in hormonally sensitive
tissues with time are often cited as being possibly related to EDCs because of the
enormous increase in production volume of chemicals since the early 20th century
(Russo & Russo, 1996).
 Breast cancer: numerous epidemiological and experimental laboratory
studies have been conducted to determine whether environmental EDCs may
contribute to an increased risk of breast cancer, but the current scientific evidence
remains uncertain about exposure to environmental EDCs and increased risk of
breast cancer (Stanford et al., 1995; Pike MC et al., 1993; Adami et al., 1995).
 Prostate cancer: exposure to certain pesticides and organochlorines has
been linked to increases in the incidence of prostate cancer in a few limited studies
(Bertazzi et al., 1987; Brown DP, 1987; Morrison et al., 1993).
 Thyroid cancer: a direct association between exposure to EDCs and thyroid
cancer has not been demonstrated (Porterfield & Hendry, 1998).
Overall, the biological plausibility of possible damage to certain human functions,
reproductive and developing systems, from exposure to EDCs seems strong when viewed
against the background of known influences of endogenous and exogenous hormones on
many of these processes. Furthermore, the evidence of adverse outcomes in wildlife and
laboratory animals exposed to EDCs substantiates human concerns.
The age at which the exposure occurs in humans is also critical to assessing potential
effects of EDCs. In utero, neonatal, childhood, and puberty appear to be critical
developmental periods potentially susceptible to interference by EDCs. For example, it has
been demonstrated that the effects of exposure to PCBs on neurobehavioral function in
children will vary depending upon whether exposure occurs prenatally or postanatally
(Jakobson and Jakobson 2001).
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The following scheme presents groups of substance able to perform endocrine disruption:
Estrogenic Chemicals
Sources
Some environmental EDCs are released into the environment intentionally (e.g.
pesticides), but for most of the environmental contaminants, release is unintentional. It
could occur throughout part or all of the chemical’s life cycle (e.g. manufacturing, use,
disposal). “Dioxin-like” chemicals are formed intentionally as by-products in a variety of
industrial and combustion process (Fara 1999; Toblin 1986). Leakage from landfill areas
and distribution via sewage sludge are also sources of exposure (Daughton et 1999).
Naturally Occurring Synthetic Contaminants
Human and animal
Estrogens
Progesterone
Testosterone
Phytoestrogens
Isoflavonoids
Flavonoids
Stilbenes
Lignans
Mycoestrogens
Pharmaceutical Estrogens
Oral contraceptives
Hormone replacement
Animal feed additives
Diethylstilbestrol
Xenoestrogens
Alkylphenols
Benzo(a)pyrene
Bisphenol A
Cosmetics
Dioxins
Pesticides
Polychlorinated biphenyls
Polybrominated diphenyl ethers
Phthalates
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Exposure to naturally occurring EDCs such as phyto- and fungal estrogens, which are
important components of some human and wildlife diets, occurs globally. The isoflavonoid
phytoestrogens are found in soy and legumes, the lignanes in grains and many fruits and
vegetables. All have relatively short-half lives in humans, and metabolites can be detected
in urine and feces. Phytoestrogens have also been detected in effluents from pulp mills,
resulting in reproductive effects in certain fish species.
Exposure can occur via air, water, soil, sediment, and food and consumer products. The
chemical may then enter the organism by ingestion, inhalation, or skin contact across cell
membranes and then be absorbed into the bloodstream (Crosby, 1998).
Some chemicals considered as EDC and their effects
PCBs. The manufacturing of PCBs has been banned in many countries since 1970a (de
March, 1998). However, because of their long lifetime in old electrical equipment,
continued use in some parts of the world, and their persistence and bioaccumulation,
populations continue to be exposed.
DDT (Dichlorodiphenyl tricthlroethane). The manufacturing and use of a number of
pesticides, including DDT, have been banned or greatly restricted. However DDT is still
used in developing countries. While the concentration of DDT metabolites is decreasing in
northern hemisphere population, in southern hemisphere these compounds are still
present at relatively high concentrations (Torres-Arreola, 1999). During the 1960s and
1970s, when DDT was present in the North American environment at greater
concentrations, population of several sensitive bird species declined because of
unsuccessful incubation of eggs due to abnormally thin egg shells (Cooke, 1973)
Phthalates. Phthalates are diester derivates of phthalic acid used primarily as plasticizers
to make plastic products more flexible. The main property of these plasticizers is to not
become a permanent (chemically bonded) part of the plastic matrix during manufacturing
process. They can migrate from plastic to environmental matrices under certain conditions.
As a result they become ubiquitous in our environment (Steiner, 1999). Some phthalates
induce antiandrogenic effects in fetal males. Male rat pups exposed during sexual
differentiation exhibited malformations in androgen-dependent tissues (Gray, 1990-2000)
Atrazine. Atrazine is a member of the triazine herbicide family and has been widely used
for weed control in agricultural crops. It is frequently found in surface water and
groundwater. Because it may be found in drinking water, its use has been banned or
INTRODUCTION
15
restricted in many countries. In the context of EDCs, there is concern about atrazine
related to the development of mammary tumors in exposed rats (Elridge, 1994; Stevens,
1994).
1.5 The nuclear receptor family
The nuclear receptor family consists of proteins that mediate the actions of many important
cell regulators. These include the steroid hormones (estrogens, progestins, androgens,
glucocorticoids, mineralocorticoids, ecdysteroids, vitamin D), thyroid hormones, and
retinoids. In contrast to receptors for peptide hormones, which are located in the cell
membrane and evoke a second messenger to deliver the regulatory signal, the nuclear
receptors are present within the cell. After associating with their respective ligands, they
eventually act as transcription factors in the cell nucleus to enhance the expression of
specific genes. Agents that act by way of nuclear receptors influence the behaviour of
many tissues in vertebrate species. Often certain cells are especially responsive. For
example, the gonadal steroid hormones control growth, differentiation, and function of
reproductive and accessory sex tissues: estrogens and progestins in the female (uterus,
vagina, oviduct, mammary gland) and androgens in the male (prostate, and seminal
vesicles). They also influence many other tissues, including skin, hair, bone, pituitary, and
the central nervous system. Steroid hormone receptors are posphorylated proteins
containing sulfhydryl groups necessary for ligand interaction. In their native state, steroid
receptors are complex entities, consisting of a hormone-binding protein associated with
other macromolecules.
The important function of the steroid is to convert the native receptor to a biochemically
functional state that can bind to the DNA and enhance gene transcription (Gorski et al.,
1968).
Many studies demonstrated that hormone induced transformation of the native receptor to
a form that can interact with target genes and that, is a general phenomenon for all
classes of steroid hormones, but not for thyroid hormones (Jensen, 1990). Much of the
native receptor for steroid hormones are present in the nucleus. To explain steroid
hormone action, the “two-step” theory was introduced, which takes its origin from the
mechanism proposed for the estradiol-receptor complex. Following this mechanism, there
is a cytoplasmic-nuclear equilibrium of the receptor and the cytoplasmic level is continually
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replenished from a nuclear pool, on the other hand there are receptors located only in the
nucleus. Once the hormone arrives in the nucleus, receptor transformation and genome
binding are initiated (Jensen, 1991).
Mechanisms proposed:
H
A B
Figure 3: Schematic representation of hormone-receptor interaction in target cell. H, hormone; Rn
native (untrasformed) receptor; Rt, transformed receptor. (A) Extranuclear receptor in equilibrium
with nuclear pool of loosely bound native receptor. (B) Native receptor confined to the nucleus
(Jensen).
Aryl hydrocarbon receptor
The aryl hydrocarbon receptor (AhR) is a cell protein that initiates many of the effects of
dioxin-like chemicals. Its primary function in the body is uncertain, and it is structurally
related to other important cell proteins involved for instance in rhythmic functions (clock
proteins) and organ development.
When a dioxin compound enters the cell, it binds to AhR, this moves from cellular
cytoplasm to nucleus, forms an heterodimer with another protein, ARNT (Ah Receptor
Nuclear Translocator), and this heterodimer binds to DNA. This binding initiates the
activation of a number of genes depending on the binding site of the dimer.
Rn HRn
HRt
HRt +DNA
Rn +H
H +Rn
HRn
HRt
HRt +DNA
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The environmental toxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), is a high affinity
ligand for the AhR and has extensively been used to investigate AhR-mediated
biochemical and toxic responses. TCDD modulates several endocrine pathways including
inhibition of 17-estradiol-induced responses in the immature and ovariectomized rodent
uterus and mammary gland and in human breast cancer cell lines (Safe S, et al., 2000).
Certain PBDE congeners can act as AhR agonists or antagonists (Meerts et al., 1998a).
Pyrolysis and photolysis of PBDEs can lead to formation of other hazardous compounds
such as Polybrominated dibenzo-p-dioxins and polybrominated dibenzofurans (Buser,
1986; Watanabe et al., 1987; Dumbler et al., 1989; Bruckmann & Hackhe 1989).
Steroid Receptors
A major mode of action of steroid hormones is regulating gene activity though nuclear
receptors, which represent ligand-activated transcription factors that share common
structural features (Kumar, 1999; White, 1998).
To this end, the receptor proteins possess characteristic domains corresponding to their
specific functional roles, for example, for DNA binding (DBD) and ligand binding (LBD),
two transcription activation domains (ligand-dependent, AF2, and ligand-independent,
AF1), sequences for nuclear localization (NLS), for dimerization, and for interaction with
nuclear and cytoplasmic proteins.
The ligand-activated receptor, as dimer, interacts with specific DNA binding sites (hormone
response elements, HRE), and with a series of nuclear proteins, among them coactivators,
acting positively on transcription, and corepressors, having negative effects on RNA
synthesis (Motsatsou, 2003).
Nuclear receptors can also act as monomers, not by direct binding to DNA, but indirectly,
through interaction with other DNA binding regulatory proteins (Reichardt, 1998).
Furthermore, nuclear receptors can cross-talk with other regulatory agents, such as growth
factors, cytokines, and neurotransmitters, in the absence of cognate ligand, by way of
phosphorylation of the nuclear receptors at serine/threonine residues by phosphokinases
activated by these molecules (Knazir, 1990).
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1.6 Estradiol
17 -Estradiol (E2) is a versatile hormone that acts on the uterus to stimulate cell
proliferation and to increase sensitivity of the uterus to progesterone. New knowledge
comes from ER knockout mouse models (ERKO and ERKO). Based on these, it
appears that ER plays the predominant role in mediating the effects of E2 in the uterus.
Estradiol exerts its effects in target organs by binding to ERs and modulating the
expression of various proteins such as growth factors. In the uterus one of such factor is
insulin-like growth factor I (IGF-I). It was shown (Klotz, 2000) that E2 administartion to
ovariectomized adult female mice and rats results in an increase in uterine IGF-1
transcripts (klotz, 2000).
1.7 Estrogen Target Genes
ANDROGEN RECEPTOR
The development, maintenance and functions of the prostate gland requires the activity of
androgen receptors (AR).
AR is a steroid hormone receptor that when activated directs the expression of target
genes by acting as a DNA-binding transcription factor. AR interacts with specific DNA
sequences or with other proteins in the regulatory regions of target genes, and recruits
cofactors that either enhance or inhibit the rate of transcription, depending on the nature of
the regulatory element. Intracellular signalling pathways, cell cycle proteins, and other
factors can modulate AR by modifying the receptor or interacting with it physically,
providing a means for cross-talk between hormonal and growth factor signals.
AR is expressed in the secretory epithelial cells, the surrounding periacinar stromal cells,
and in perivascular smooth muscle of the prostate.
Few direct targets of AR in the prostate are known, and the genes immediately
downstream of AR in the prostate that regulate proliferation and differentiation remain
largely uncharacterised. Because AR acts primarily as transcription factor, differential
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gene expression studies are an ideal means to study the effects of AR in prostate cells
(Pascale, 2003).
ESTROGEN RECEPTORS
Estrogen regulates the growth and differentiation of the uterus via binding to estrogen
receptors (ERs), members of the nuclear receptor family of transcription factors. The
diverse effects of estrogen on a wide range of target tissues are mediated by estrogen
receptors (ERs), nuclear transcription factors that are activated either upon binding of
estrogen and estrogen-like ligands or via cross-talk, most likely through phosphorylation of
the unliganded receptors, with various other signal transduction pathways (Suresh, 2002).
Two forms of ER exist: ER and ER. The former is a well-characterized mediator of
estrogen-induced transcription, but the function of the latter is unclear and has
necessitated a complete re-evaluation of estrogen signalling pathways in target cells.
ER is expressed in ovary, uterus, vagina, mammary gland, and in central nervous system
(CNS), whereas ER is expressed in the ovary, in the endometrium and myometrium, and
is highly expressed in the CNS (Kuiper, 1997; Shughrue, 1998).
The cyclic growth and differentiation of the uterine endometrium and other tissues of the
reproductive tract are controlled in large part by estrogen.
While the predominant ER in the uterus is ER, numerous investigators have reported that
ER is also expressed there, albeit at a markedly lower level (Kiper, 1997).
The differences in tissue and cell distribution of the two receptors are one of the factors
underlying the tissue-specific response to estrogenic compounds.
There is relatively little known about the regulation of ER expression and role in target
tissues. Most of the information regarding the role of these receptors stems from studies of
transgenic mice in which either one or both receptor genes have been knocked out.
Analysis of these animals led to the conclusions that ER is a modulator of ER and has
anti-uterotrophic effects, possibly by inhibiting the expression of IGF-I and down-regulation
of progesteron receptor (PR) (Hall J.M, et al., 1999; Couse J.F et al., 2000). In the ovary,
ER is down-regulated by gonadrotopin treatment (Byers et al., 1997), while estrogen has
been reported to reduce ER expression in some areas of the brain and in the pituitary
(Osterlend et al., 1998)
ER and ER exhibit distinct interactions with common or specific cofactors, show
differential binding to a variety of ligands, and may act by way of different response
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elements, exhibiting altered specificity and affinity (Muramatsu, et al., 2000; Hall et al.,
1999).
ER and ER can form homo- or heterodimers (ER/ER), and the formation of
heterodimers is probably the reason for the inhibitory action of ER on ER-induced
transcription.
PROGESTERONE RECEPTOR
Progesterone (P4) is a key coordinator of female mammals, it directly regulates many
functions, such as reproductive behaviour, uterine growth, and implantation. Most actions
of P4 are mediated by the progesterone receptor (PR).
PR is a member of the steroid-retinoid receptor superfamily of ligand-activated
transcription factors, which mediate genomic effects of gonadal steroids. In the most
species, PR is composed of two major ligand-binding forms (the long B form and a N-
terminal truncated A form) encoded by one gene ( Graham JD. Et al. 1997).
Progesterone receptor is one of the best studied estrogen-regulated genes and is widely
recognized as a marker for estrogen action. Regulation of the PR gene by estrogen has
been extensively studied. Within the PR gene promoter, clusters of estrogen response
element (ERE) half-sites are present, which are essential for transactivation of the PR
gene by liganded ER (Kastner P. et al., 1990).
Since the PR protein level is thought to be a critical determinant of sensitivity to P4, almost
all hormone treatment protocols designed to elicit effects of P4 usually involve previous
estrogen priming to induce PR (Kurita et al., 2001).
INSULIN-LIKE GROWTH FACTOR-I
Insulin-like growth factor-I (IGF-I) is a single chain basic polypeptide of 70 amino acids
with molecular mass of 7649 Da. (Rinderknecht et al., 1978). It has high structural
similarity with pro-insulin, as its name indicates. Using molecular biology techniques it has
been proven that IGFs are highly conserved proteins found in an array of vertebrates
species.
IGF-I is an important growth factor that depends very much on the tissue: in the brain it
has also differentiating effects.
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IGF-I is produced in liver, bone cells and other tissues, stimulates somatic growth and is
essential in cell growth and metabolism. Its serum levels are involved in pathogenesis of
disease, such as diabetes, cardiovascular diseases, cancer and osteoporosis (Kajantie et
al., 2003; Brixten et al., 1986). It is also known to have a broad range of effects including
promotion of cell survival, stimulation of metabolism, proliferation and differentiation of
cells. Levels are influenced by growth hormone (GH), insulin and nutrition, but these
factors only partly explain the wide variation in the levels. Studies on the role of IGF-I have
been hampered by the fact that circulating IGF-I levels do not necessarily reflect the local
production of IGF-I in specific tissues, such as pancreatic beta cells, myocardium, bone
cells or CNS. Over 90% of IGF-I is bound to specific IGF binding proteins, of which IGF-
BP3 appears to be most frequent. A genetic polymorphism in the promoter region of IGF-I
production (Rietveld et al., 2003). The receptor to this hormone is a tyrosine kinase.
Many compounds, including dyes, fluorides, etc. have been registered in patents for their
capability to mimic the physiological activity of insulin or insulin-like growth factor (Amman
et al., 1998). There is some evidence from experimental studies that IGF-I could be a
mediator of the actions of E2 in the uterus (Richards et al., 1996).
1.8 Rat reproductive organs
The Prostate
The principal function of the prostate is to provide the proteins and ions that form the bulk
of the seminal fluid.
The rodent prostate is composed of well defined lobes (dorsal, lateral and ventral), each
with unique patterns of ductal branching and lobe-specific secretory proteins. These lobe-
specific morphologic and functional differences appear to be induced by distinct
subpopulations of mesenchyme within the urogenital sinuses. Dorsal and ventral portions
have different inductive properties (Hayward et al., 2000).
Prostatic budding is initiated by prenatal androgenic action. Ductal branching
morphogenesis, canalisation, and epithelial cytodifferentiation also require androgenic
stimulation. In rodent models the majority of ductal branching morphogenesis occurs
between birth and puberty when circulating androgen levels are low. At puberty there is a
growth spurt characterized by an increase in prostatic wet weight but only a small increase
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in the number of ductal tips (Sugymura et al., 1986). Data from Sugymura et al., indicate
that the developing prostate is sensitive to low androgen titers for ductal branching
morphogenesis and that its response to increased androgen levels at puberty (an increase
in wet weight) is separate from the early ductal branching.
The physiological role of estrogens in the prostate is unclear; however, estrogens can give
rise to squamous metaplasia (Walsh et al., 1997). Presumably, the estrogens influence
prostate development and differentiation through ERs. In the rat, ER has been localized
by immunohistochemistry and by in situ hybridisation to periductal stromal cells and not to
epithelial cells (Prins et al., 1997). ER is known to be expressed at high levels in epithelial
cells of the rat prostate gland, but its regulation is not well known (Prins et al.,1998, Asano
et al., 2003).
The Uterus
The uterus of the rat is classified as uterus duplex. The lumina of the uterine horns are
completely separate and open as a paired external orifice. A partial fusion of the two horns
occurs caudally in that they share a common outer longitudinal layer of myometrium
(Anatomy of the laboratory rat).
Uterus is a major target tissue for ovarian hormones, it is composed of heterogeneous cell
types (stromal, luminal, epithelial, glandular, epithelial, and smooth muscle) that undergo
continuous syncronized changes of proliferation and differentiation in response to changes
in levels of circulating estrogen and progesterone (Li S., 1994; Martin et al., 1997). All of
the gonadal steroid hormone receptors, ER, ER, PR and AR are expressed in this
organ. Estrogen, by regulating estrogen target genes in a cell-specific manner, has
different effects on different types of cell in the uterus. Proliferation is initiated at puberty in
response to cycling estrogen, although the immature uterus is fully capable of responding
to estradiol (E2), and estrogen induces both epithelial and stromal cell proliferation (Martin
et al., 1973). Although ER is highly expressed in the epithelium, proliferation of epithelial
cells in response to E2 is thought to be indirect, i.e., growth factors secreted by stroma in
response to estrogen are the mitogens in epithelium (Cooke P.S., et al.,1997) ER plays
an important role in differentiation by regulating target genes such as that for the
progesterone receptor (PR) Both the stroma and epithelium express PR, and estrogen
induces PR in the stromal and glandular epithelial cells, whereas it reduces it in the luminal
epithelial cells (Tibbetts T. A. et al., 1998). The mechanism behind the cell specific
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regulation of PR by estrogen remains unclear and could not be fully explained if all of the
actions of estrogen in the uterus were mediated by ER. The role of ER in uterus is not
fully understood. ER can act as a transdominant repressor on ER transcriptional activity
at subsaturating concentration of E2 (Hall, J.M et al., 1999). One explanation for the
inhibitory effects of ER on ER function is that ER can form heterodimers with ER
which in turn regulate ER functions (Petersson, K., et al 1997; Cwley S.M., et al., 1997).
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2. Aim of the Study
Polybrominated diphenyl ethers (PBDEs) are a novel class of environmental contaminants.
They are bioaccumulated and biomagnified in the environment, and comparatively high
levels are often found in aquatic biotopes from different parts of the world. An exponential
increase of PBDE levels has been observed in Swedish mother’s milk during a period from
1972 to 1997. Based on levels in food from 1999, the dietary intake of PBDE in Sweden
has been estimated to be 0.05 g per day. Since human milk is an indicator of the level of
exposure of the maternal organism and hence of possible exposure of the fetus, and on
the other hand, of the level of exposure of nursing infant, investigations of the
developmental toxicity of PBDEs were considered to be necessary.
Up to now, knowledge on PBDE’s effect has been quite limited. The main data gaps
concern reproduction, developmental toxicity and carcinogenicity. Many international and
national authorities realised the need for further investigations supporting several project s
to identify more clearly the actions of PBDEs in mammals. The aim of this EU-funded
study was to provide informations on developmental toxicity of PBDE. One of major
components of commercial PBDE products, PBDE 99 (2,2’,4,4’,5-Pentabromo-
diphenylether) which also is one of the most abundant congeners in human milk, was
chosen.
The doses of PBDE 99 selected were 1 mg/kg/day (the LOAEL) and an high dose of 10
mg/kg/day. The 1 mg/kg was taken from preliminary results indicating developmental
(behavioural) toxicity of PBDE 99 in mice at this dose level (Eriksson et al., 2001; Viberg et
al., 2003)
Since PCBs have a similar structure to PBDE, Aroclor 1254 was selected as positive
control.
The aim of the experiments conducted in our laboratory was to clarify possible effects of
PBDE 99 (in comparison with PCB) on the development of reproductive organs at the
organ level and gene expression level. Data on actions of PBDE on endocrine
mechanisms were not conclusive, but interactions seemed possible, also in view of the
structural relationship to PCBs.
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3. Material and Methods
3.1. Chemicals
The chemicals tested were: 2,2’,4,4’,5-Pentabromodiphenylether (PBDE99) and an
commercial mixture of polychlorinated biphenyls (PCB) Aroclor 1254, both provided by
Promochem GmbH, Wesel, Germany. PBDE 99, as powder with purity > 99% was stored
in a glass tube at room temperature and protected as much as possible from light
exposure. The PBDE 99 solutions were prepared by dissolving PBDE in a few drops of
Toluene ( Scharlau ) and adding a volume of sterile olive oil which also served as negative
control. The toluene was being evaporated by a magnetic stirrer. Two different
concentrations were prepared: 10mg of PBDE99 per 1 ml of olive oil and 1mg PBDE99/
1ml olive oil.
Aroclor 1254 solutions (10mg/ml and 30mg/ml of olive oil) were prepared by mixing it with
a volume of olive oil. All solutions were stored at +4°C.
3.2. Animals
The study was conducted on offspring of time-pregnant Long-Evans rats bred in our
laboratory.
They were originally derived from Mollegard Breeding & Research Centre Denmark.
Groups of 3-4 animals of the same sex were kept in (19 x 38 x 60 cm) plexigas cages
housed in rooms with regular light/dark cycle (light on 02.00-16.00 h), controlled
temperature and humidity (22 °C ± 1°C; 50%). They were fed with standard diet (Provimi
Kliba AG, Kaiseraugst, Switzerland) and water ad libitum.
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3.3. STEADY STATE LEVELS ANALYSIS (BASELINE ANALYSIS)
3.3.1 Experimental animals and prenatal exposure to the chemicals
The age of animals used for time-pregnant mating was a maximum of 6 months old for
females and 12 months for males.
One receptive female was mated overnight with one male. The stage of pregnancy was
defined as GD 1= 24 h after onset of mating.
Females exhibiting positive vaginal smears after time-pregnant mating and a consistent
gain of weight till gestational day 9 (GD9) were housed in separate groups of two animals.
They were treated with one daily injection (s.c.) from GD 10 till GD18 (9 injections) with
PBDE 99 (1 or 10 mg/kg/day), or Aroclor 1254 (10 or 30 mg/kg/day) or vehicle control
(olive oil), 0.1ml/ 100 g. body weight injection volume. At GD22 the pregnant females were
separated.
3.3.2 Postnatal investigations
Offspring were investigated after birth for several developmental endpoints such as weight,
righting reflex, ano-genital distance, and eye opening at fixed age points following a
reprotox plan protocol. Mother behaviour was also observed. The litter size was adjusted
to 8 - 10 pups per each litter in order to have comparable conditions between the
treatment groups.
Reprotoxplan:
-Postnatal day (PN) 2: body weight, ano-genital distance, righting reflex, milk consumption,
maternal behaviour, equalization of offspring number.
-PN4: body weight, righting reflex, milk consumption and maternal behaviour
-PN6: body weight, ano-genital distance, righting reflex, milk consumption, maternal
behaviour and equalization of offspring number.
-PN8: body weight and righting reflex
-PN9: body weight, ano-genital distance, righting reflex and eye opening.
-PN14: body weight, ano-genital distance, righting reflex, eye opening, maternal behaviour
and equalization.
-PN28: weaning from the mother.
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-from PN34: puberty onset in females (vagina opening).
-fromPN41: puberty onset in males (preputial separation).
3.3.3 TISSUE PREPARATION
Animals at around 120 days of age were sacrificed by decapitation, the females always in
metestrus=diestrus 1. Uterus, ventral and dorsal prostate were removed, weighed (wet
weight), frozen with metylbuthane (Fluka) and stored in liquid nitrogen. Ovaries, testis and
epididymis were weighed and stored (ovaries in 70% formalin, testis in ethanol, and
epididymis at –80°C). Liver, coagulating glands and seminal vescicles were only weighed.
Adipose tissue and serum were collected and stored at –20°C.
3.3.4 mRNA Quantification
Homogenization
The tissues being analysed for mRNA (uterus, ventral and dorsal prostate) were disrupted
in a solution of RLT-puffer (Qiagen no.79216) and β-mercaptoethanol (Fluka) and
homogenized by rotor (Politron-aggregate, Kinematica, Luzern CH). Ratio between RLT-
buffer and β-mercaptoethanol: 1ml/10µl. Ratio between tissue weight and buffer
20mg/350µl. The homogenate was then centrifuged for 10 min at 3000 x g at 20 °C. After
centrifugation, the supernatant was collected and stored at –80°C.
RNA extraction
Total tissue RNA was extracted following the handbook and using reagents from RNeasy
Mini Kit (Qiagen cat. no. 74106) according to instructions by the company. Genomic DNA
was thoroughly digested by DNAse-I (Qiagen).The concentration of RNA was determined
by measuring the absorbance at 260 nm wave-length at several RNA dilutions. Pure RNA
was stored in aqueous solution at –80°C till use.
The procedure steps were the following:
1. 350µl volume of clear supernatant was transferred into a clean tube and mixed with
the same amount of Ethanol 70%.
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2. The total mixture was applied to a Rneasy column, centrifuged for 15 sec at 11,000
g and the flow-through discarded.
3. 350µl RW 1 buffer was added to the column, centrifuged and flow-through
discarded.
4. 80µl DNase I was added and incubated for 15 min at room temperature.
5. 350µl RW 1 buffer was added to the column, centrifuged, flow-through discarded
and the column was transferred into a new clean tube.
6. The column was washed twice with RPE puffer with ethanol 70%.
7. At this point the column was eluted with 50µl of RNAse free water.
Reverse transcription
Reverse transcription of RNA to cDNA was performed by using TaqMan Reverse
Transcription Reagents kit according to manufacturer’s instructions (Applied Biosystems
N808-0234, Rotkreuz, Switzerland). The procedure followed is illustrated in the table
below:
Table 3.1: Reverse Transcription reaction mix
RT component 1x100 µl End concentration
H20 18.5
10 x TaqMan RT buffer 10 1x
25 mM Magnesium Chloride 22 5.5 mM
DeoxyNTP’s mixture 20 500 µM of each dNTP
50 µM RT primer* 5 2.5 µM
RNase Inhibitor 2 0.4 U/µl
MultiScribe TM Reverse
Transcriptase
2.5 1.25 U/µl
RNA in H2O 20 10 ng/µl in total volume
*Random hexamers as primer was used.
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The reverse transcription polymerise chain reaction was performed with the conditions
shown in the table 3.2:
Table 3.2: RT cycle
Incubation Reverse Transcription Reverse Transcription
Inactivation
EndStep
Hold Hold Hold Hold
Time (min) 10 min 30 min 5 min
Temperature (°C) 25°C 48°C 95°C 4°C
At the end, the RT products (cDNA) were stored at –20°C.
Primer and Probe Sequence for real time PCR (5′ 3′)
The gene sequence for primers and probes were designed by selecting an amplicon
region from mRNA sequence (National Cancer for Biotecnology Information, gene bank)
specific for each gene (AR, PR, IGF-1, ERα, ERβ and CycA) with PrimerExpress
Software, Version 2.0. Each probe was labelled at 5′ end with FAM as reporter.
Androgen Receptor (AR) :
Forward Primer: 5’-CGGAAGGGAAACAGAAGTATCTATG-3’
TaqManProbe: 5’-CCAGCAGAAATGATTGCACCATTGATAAATTTC-3’
Reverse Primer: 5’-GGAGACGACACGATGGACAA-3’
Progesterone Receptor (PR):
Forward Primer: 5’-GCAATTGGCTTAAGACAGAAAGG-3’
TaqManProbe: 5’-CCCAGTTCACAACGCTTCTATCAACTTACAAAAC-3’
Reverse Primer: 5’-ACAAGATCATGCAAGCTGTCAAG-3’
Insulin Growth Factor-I (IGF-I):
Forward Primer: 5’-GGCCCAGCGCCACA-3’
TaqManProbe: 5’-TGACATGCCCAAGACTCAGAAGGAAGTACA-3’
Reverse Primer: 5’-TGTTTCCTGCACTTCCTCTACTTG-3’
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Estrogen Receptor α (ERα):
Forward Primer: 5’-CCAAAGCCTCGGGAATGG-3’
TaqManProbe: 5’-TCGTTCCCTTGGATCTGGTGCAACAA-3’
Reverse Primer: 5’-AGCTGCGGGCGATTGAG-3’
Estrogen Receptor β (ERβ):
Forward Primer: 5’-TTGGTGTGAAGCAAGATCACTAGAG-3’
TaqManProbe: 5’-CCACTAAGCTTCCTCTTCAGTGTCTCTCTGTTTACA-3’
Reverse Primer: 5’-AACAGGGCTGGCACAACTG-3’
Cyclophillin A (Cyc):
Forward Primer: 5’-TGTGCCAGGGTGGTGACTT-3’
TaqManProbe: 5’-CCACCAGTGCCATTATGGCGTGT-3’
Reverse Primer: 5’-TCAAATTTCTCTCCGTAGATGGACTT-3’
They were ordered by Microsynth (Balgach, Switzerland) and diluted in H2O, primers to
9000 nM and probes to 2250nM and stored at –20°C.
Real Time PCR reaction
For the mRNA quantification by Real Time-PCR, every reaction run was done on a 96 well
plate with 25 µl of reaction-mix pro each well.
The reaction-mix components are listed in the scheme below:
Table 3.3: Real Time-PCR component mix.
Reagents Volume/tube µl End concentration
TaqMan Universal PCR Master Mix 12.5 1x
Forward primer 2.5 50-900nM
Reverse primer 2.5 50-900nM
TaqMan probe 2.5 25-225nM
DNA sample (cDNA from the
investigated gene)
2.5 0.2-2ng/µl
Water 2.5
Total volume 25
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TaqMan universal PCR Master Mix was purchased from Applied Biosystems as well as the
plates. Probe, forward and reverse primers were ordered from Microsynth. Real Time-PCR
was performed on the ABI PRISM 7700 Sequence Detector (Applied Biosystems).
The detecting run was composed of different step cycles which are described in the
following scheme:
Table 3.4: detection run steps.
Times and Temperatures
Each of 50 Cycles
Thermal Cycler
Initial Steps
Melt Anneal/Extend
Hold Hold CycleABI PRISM 7700
Sequence Detector 2 min
50°C
10 min
95°C
15 sec
95°C
1 min 60°C
At the end of each run all the data were analysed using the Standard Curve Method.
A standard curve (cDNA diluted 1:2 four times) for the reference gene (cyc.) and for the
gene of interest was included in each plate. mRNA concentration was calculated by
plotting the Ct value to the respective standard curve.
3.4. ACUTE ESTROGEN CHALLENGE-STUDY
3.4.1 Experimental animals
Adult male and females Long Evans rats were obtained from Janvier (Le Genest St. Isle,
France). Time-pregnant dams were treted with either 1mg/kg/ day or 10 mg/ kg/ day PBDE
99, 10 mg/ kg/ day Aroclor 1254, or vehicle from GD 10 until GD 18, and their offspring
were raised until adulthood as described in the “Steady State” section.
3.4.2 Gonadectomy
At 10 weeks of age male and female F1 offspring were bilaterally gonadectomized under
anesthesia to remove the primary source of sex hormones.
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The following mixture was used for anesthesia:
Table 3.5: anesthesia components.
Components Volume 10ml
Fentanyl citrate and fuanisone (Hypnorm Janssen) 1.25 ml
Medetomidine (Domitor Pfizer) 1.25 ml
Atropinsulfat 0.1% (Atropin Kantonsapotheke ZH) 0.25 ml
Tap Water 7.25 ml
Injection volume per each animal was: 150 µl/100g body weight.
3.4.3 Tissue preparation
Two weeks after gonadectomy the animals were given a single subcutaneous injection of
17-β Estradiol (E2) (Calbiochem Lucerne, Switzerland). Vehicle controls were injected with
10µg/kg body weight dissolved in ethanol and then dimethylsulfoxide (DMSO, Fluka) or
olive-oil.
Six hours after the injections, the animals were sacrificed by decapitation.
Uteri from females and ventral prostate from males were quickly removed, frozen with 2-
methylbutane and stored in liquid nitrogen.
3.4.4 Determination of mRNA levels
The procedure followed was as used for the Steady State series. The only exception was
the disruption of ventral prostate (vp) pieces, which was performed in a sonicator instead
of homogenizer because of small size of the ventral prostate in gonadectomized animals.
3.5 STATISTICAL ANALYSES
All data were expressed as mean ± SD. The statistical analysis was done using SYSTAT
Version 5.02 for Windows. All treatment groups were compared by one-way analysis of
variance (ANOVA), followed by pair wise comparison by Bonferroni test.
Significant differences are indicated as following: p < 0.05 marked with: *, p range between
0.01 and 0. marked with **, p < 0.001 shown as ***.
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3.6 Study design:
3.7 Synopsis of treatment groups:
Prenatal Treatment
GD10GD18 Sex Adult Treatment
Steady State Study:
• PBDE 1 mg/kg/day
• PBDE 10 mg/kg/day
• Aroclor 10 mg/kg/day
• Aroclor 30 mg/kg/day
• Vehicle
Male
F1
Female
F1
No adult treatment
Estrogen Challenge
Study:
• PBDE 1 mg/kg/day
• PBDE 10 mg/kg/day
• Aroclor 10 mg/kg/day
• Vehicle
Male
F1
Female
F1
Gondectomy+ acute Vehicle
Gonadectomy+acute10 g/kg E2
•Steady state conditions mRNA levels of estrogen
target genes in reproductive organs in adult male
and female rats.
GD10 GD22=PN1
Acute estrogen-challenge
6h after single s.c. injection
of 17ß-Estradiol
mRNA levels of estrogen
target genes in rat
reproductive organs.
9 s.c. inj.
Gonadectomy
PN84=100/120
GD18
PN70
  	 
 
PBDE 99
1 mg/kg/day
10 mg/kg/day
Aroclor 1254
10 mg/kg/day
30 mg/kg/day
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4. Results
4.1 Samples and litter size
The total number of samples and litters per each treatment are listed in the table below,
divided in males and females.
Male rat offspring:
Treatments Number of animals Number of litters
Control (C) 20 9
PBDE99 1mg/kg (P1) 14 7
PBDE99 10mg/kg (P10) 22 9
Aroclor 10mg/kg (Aro10) 20 5
Aroclor 30mg/kg (Aro30) 12 4
Female rat offspring:
Treatments Number of animals Number of litters
Control (C) 18 9
PBDE99 1mg/kg (P1) 12 7
PBDE99 10mg/kg (P10) 10 9
Aroclor 10mg/kg (Aro10) 13 5
Aroclor 30mg/kg (Aro30) 6 4
4.2 Surviving Rate
The surviving rate from post-natal day 2 (PN2) till PN 14 was not altered in treatment
groups compared to control animals (fig. 4.1).
4.3 Onset of
Puberty
the onset of puberty was
checked by
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Figure 4.1: surviving rate
from PN2 to PN14, in
treatment groups:
Control, PBDE99 1
mg/kg (P1), PBDE9910
mg/kg (P10), Aroclor
1254 10 mg/kg (Aro 10)
and Aroclor 1254 30
mg/kg (Aro30). Data
represent the % of all
offspring per each
treatment that reached
PN14.
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4.3 Onset of Puberty
The onset of puberty was checked by preputial separation in males and vagina opening in
females. In males there was an early preputial separation in both PBDE 99 doses while in
females there was a delay in PBDE 99 10 mg/kg dose group and in Aroclor 1254 30 mg/kg
dose group (fig. 4.2).
Preputial Separation
45.0 45.5 46.0 46.5 47.0 47.5 48.0 48.5 49.0
1
Postnatal Days
CON
PBDE 1
PBDE 10
Aro 10
Aro 30
*
*
Vaginal Opening
38.0 38.5 39.0 39.5 40.0 40.5 41.0 41.5 42.0 42.5 43.0
1
Postnatal Days
CON
PBDE 1
PBDE 10
Aro 10
Aro 30*
*
Figure 4.2: onset of
puberty in male and
female offspring in
treatment groups:
Control, PBDE99 1 mg/kg
(P1), PBDE9910 mg/kg
(P10), Aroclor 1254 10
mg/kg (Aro 10) and
Aroclor 1254 30 mg/kg
(Aro30). Data represent
the post-natal days when
preputial separation and
vagina opening took place.
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4.4 Body weight
The body weight of adult offspring studied at postnatal day (PN) 120 was not affected by
prenatal treatment with PBDE99 (fig. 4.3). No significant change was observed. In
females, there seemed to be a tendency toward a decrease in the low dose treatment
group but the p value is > 0.05 (fig. 4.4).
Table 4.1: Body weight adult males.
Treatment Mean (g) S.D. n
C 398.2 ±29.3 20
P1 405.6 ±25.3 14
P10 414.8 ±28.4 22
Aro10 369.2 ±31.9 20
Aro30 370.8 ±61.5 12
Male Body Weight
0
50
100
150
200
250
300
350
400
450
500
C P1 P10 Aro10 Aro30
Treatments
g
Figure 4.3: male adult body weight in different treatment groups: Control, PBDE99 1 mg/kg (P1), PBDE9910
mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro30). Data are represented as mean
values ±S.D. and expressed in grams.
Table 4.2: Body weight adult females body weight.
Treatment mean (g) S.D. n
C 244.2 ±25.2 18
P1 229.2 ±16.7 12
P10 240.8 ±15.1 10
Aro10 226.9 ±22.2 13
Aro30 178.4 ±53.4 6
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Females Body Weight
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Figure 4.4: female adult body weight in different treatment groups: Control, PBDE99 1 mg/kg (P1), PBDE9910
mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro30). Data are represented as mean
values ±S.D, and expressed in grams.
4.5 Organ weights
All organ wet weights were measured immediately after their removal. Absolute organ wet
weight and organ wet weight normalized to body weight were considered. Asterisks
indicate significant changes (p<0.05) compared to control group.
4.5.1 Males
Ventral Prostate
The absolute wet weight of ventral prostate did not show any relevant change. A
significant increase was observed in relative weight (organ weight /body weight of the
animal) in animals exposed to 1 mg/kg of PBDE 99 (p = 0.011) (fig. 4.6).
Table 4.3: ventral prostate weight.
Absolute Weight Relative Weight
Treatment mean (g) S.D. mean S.D. n
C 0.291 ±0.082 0.000727 ±0.000184 20
P1 0.368 ±0.073 0.000916* ±0.00022 14
P10 0.310 ±0.102 0.000773 ±0.000213 22
Aro10 0.289 ±0.067 0.000744 ±0.000142 20
Aro30 0.138 ±0.046 0.000475 ±0.000362 11
* Different from Control p= 0.011
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Figure 4.5: ventral prostate absolute wet weight mean in all treatment groups: Control, PBDE99 1 mg/kg (P1),
PBDE9910 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro30). Mean values ±
S.D. are expressed in grams.
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Figure 4.6: ventral prostate relative wet weight in all treatment groups: Control, PBDE 99 1 mg/kg (P1), PBDE
99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro30). Ventral prostate wet
weights (g) were normalized to animal body weight (g). Data represent mean ± S.D.
Dorsal Prostate
The absolute weight of dorsal prostate (fig.5) was found to be affected by exposure to the
high PBDE 99 dose, with a significant increase (p=0.034). The same tendency was also
observed in relative weight (fig. 4.8) with a p value on the borderline (p=0.05).
Table 4.4: dorsal prostate weight mean ±S.D.
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Absolute Weight Relative Weight
Treatment mean S.D. mean S.D. n
C 0.259 ±0.082 0.000651 ±0.000208 20
P1 0.311 ±0.069 0.000765 ±0.000155 13
P10 0.318* ±0.089 0.000772* ±0.000213 22
Aro10 0.282 ±0.061 0.000725 ±0.000127 20
Aro30 0.197 ±0.146 0.00053 ±0.000402 12
* Different from Control with p< 0.05
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Figure 4.7: dorsal prostate absolute wet weights (g) in all treatment groups: Control, PBDE 99 1 mg/kg (P1),
PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro30). Data are shown
as mean ± S.D. Significant different from control * (p<0.05).
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Figure 4.8: dorsal prostate relative wet weights in all treatment groups: Control, PBDE 99 1 mg/kg (P1), PBDE
99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro30). Dorsal prostate wet
weights (g.) were normalized to animal body weight (g). Data represent mean ± S.D. Significance against control
is shown by * (p<0.05).
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Testis
The combined weight of both testes did not show any changes absolute or relative weight
of testis (fig. 4.9-4.10).
Table 4. 5: testis weight (g) (mean ±S.D).
Absolute Weight Relative Weight
Treatment mean S.D. mean S.D. n
C 3.11 ±0.21 0.00783 ±0.000588 20
P1 3.11 ±0.18 0.00769 ±0.000642 14
P10 3.14 ±0.23 0.00768 ±0.000933 21
Aro10 2.92 ±0.51 0.00766 ±0.0019 15
Aro30 3.06 ±0.46 0.00827 ±0.000933 12
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Figure 4.9: testis absolute combined weights (g) in all treatment groups: Control, PBDE 99 1 mg/kg (P1), PBDE
99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro30). The data represent the
mean ± S.D. of all wet weight within every treatment group.
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Figure 4.10: testis relative wet weight in all treatment groups: Control, PBDE 99 1 mg/kg (P1), PBDE 99 10
mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro30). Testis wet weights (g) were
normalized to animal body weight (g). Data represent means ± S.D.
Epididymis
The absolute combined weight of epididymis (fig. 4.11) was reduced in offspring of the low
dose groups of PBDE99 (p=0.012) and Aroclor (p=0.016). The relative weight (fig. 4.12)
showed a decrease with both PBDE 99 treatments with p values of 0.012 for P1 and 0.013
for P10.
Table 4.6: epidydimis combined weight (mean ± S.D).
Absolute Weight Relative Weight
Treatment mean (g) S.D. mean S.D. n
C 1.23 ±0.22 0.0031 ±0.00063 20
P1 1.08* ±0.08 0.0027* ±0.00022 14
P10 1.13 ±0.14 0.0027* ±0.00037 22
Aro10 1.09* ±0.21 0.0028 ±0.00066 20
Aro30 1.33 ±0.22 0.0036 ±0.00080 12
* Different from Control with p< 0.05
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Figure 4.11: epididymis absolute wet weight (g) both epididymis combined in all treatment groups: Control,
PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg
(Aro30). Data represent mean ± S.D. of all wet weight within every treatment group. Significant difference from
control shown by* (p<0.05).
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Figure 4.12: epididymis relative wet weight. The weights of both epididymis combined (g) in all treatment
groups: Control, PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor
1254 30 mg/kg (Aro30. Epidymis wet weights (g.) were normalized to animal body weight (g). Data represent
mean ± S.D. Significant differences from control are shown by * (p<0.05).
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Coagulation Glands
The absolute combined coagulation glands weight (fig. 4.13) is affected with a decrease by
Aro 10 exposure (p=0.000). The relative weight (fig. 4.14) did not show a significant
increase.
Table 4.7: coagulation glands combined weights (mean ± S.D).
Absolute Weight Relative Weight
Treatment mean (g) S.D. mean S.D. n
C 0.1179 ±0.06187 0.0002954 ±0.0001554 20
P1 0.1221 ±0.04600 0.0003012 ±0.0001081 14
P10 0.122 ±0.0204 0.0002968 ±6.85E-05 18
Aro10 0.092*** ±0.0407 0.0002131 ±7.3326-05 17
Aro30 0.056 ±0.02828 0.0001457 ±6.654E-05 6
*** Extreme significant from Control (p<0.001)
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Figure 4.13: coagulation glands absolute wet weight (g). The weights of coagulation glands combined (g) in all
treatment groups: Control, PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10)
and Aroclor 1254 30 mg/kg (Aro 30). The data represent the mean ± S.D. of all wet weight within every
treatment group. Extreme significances from control are shown by *** (p<0.001).
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Figure 4.14: coagulation glands relative weight. The weights of coagulation glands combined (g) in all treatment
groups: Control, PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor
1254 30 mg/kg (Aro 30). Coagulation glands relative wet weights (g) were normalized to animal body weight (g).
Data represent means ± S.D.
Seminal Vesicles
The absolute combined weight of seminal vesicles (fig.4.15) did not show any significant
change after PBDE 99 exposure, while with Aro10 there was a highly significant increase
in absolute as well as relative weight (p=0.000) (fig. 4.16).
Table 4.7: seminal vesicles combined weight (mean ± S.D).
Absolute Weight Relative Weight
Treatment mean (g) S.D. mean (g) S.D. n
C 0.948 ±0.158 0.00238 ±0.000367 20
P1 0.894 ±0.252 0.00226 ±0.000702 14
P10 0.706 ±0.217 0.00190 ±0.00054 21
Aro10 1.000*** ±0.151 0.00248*** ±0.000409 19
Aro30 0.977 ±0.144 0.00234 ±0.000317 11
*** Highly significant from control (p< 0.001)
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Figure 4.15: seminal vesicles absolute combined weight (g). The data represent the mean ± S.D. of all wet weight
within every treatment group: Control, PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg
(Aro 10) and Aroclor 1254 30 mg/kg (Aro 30). Significant differences from control are shown by*** (p<0.001).
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Figure 4.16: seminal vesicles combined relative wet weight (g). Seminal vesicles relative wet weights (g) were
normalized to animal body weight (g). Data represent means ± S.D The data represent the mean ± S.D. of all wet
weight within every treatment group: Control, PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10
mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro 30). Extremely significances are shown by *** (p<0.001).
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Liver
Absolute and relative wet weight of liver did not show any relevant change (fig. 4.17-18).
Table 4.8: Liver wet weight (means ± S.D).
Absolute Weight Relative Weight
Treatment Mean (g) S.D. Mean S.D. n
C 13.3 ±1.03 0.0337 ±0.00267 20
P1 12.8 ±1.23 0.0317 ±0.000294 14
P10 12.9 ±0.85 0.0311 ±0.00246 22
Aro10 13.2 ±2.21 0.0356 ±0.00630 20
Aro30 13.2 ±1.80 0.0356 ±0.00273 12
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Figure 4.17: liver absolute wet weight (g). Data represent the mean ± S.D within every treatment group: Control,
PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg
(Aro 30).
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Figure 4.18: liver relative wet weight. Liver relative wet weights (g) were normalized to animal body weight (g)
Data represent means ± S.D within every treatment group: Control, PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg
(P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro 30).
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Overview of organ weight in males
A general overview of the effects of PBDE99 and Aroclor 1254 on organ weights of adult
offspring is given in the following schemes (scheme 4.1-2):
Absolute organ weight in male rat offspring:
P1 P10 Aro10 Aro 30
Ventral Prostate
Dorsal Prostate
Testis
Epididymis
Coagulation
glands
Seminal
Vescicles
Liver
Scheme 4.1: absolute wet weight (g) in males. Significant differences from control are indicated with arrows. The
number of arrows indicates the significance level compared to the control group. Empty cells indicate no
significant change.
Relative organ weight in male rat offspring:
P1 P10 Aro10 Aro 30
Ventral Prostate
Dorsal Prostate
Testis
Epididymis
Coagulation
glands
Seminal
Vescicles
Liver
Scheme 4.2: relative organ weight in males. Wet weight was normalized to animal body weight. Significant
differences from controls indicated by arrows. Their numbers indicate the significance levels compared to
control treatment group. Empty cells indicate no significant changes.
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4.5.2 Females
Uterus
The absolute weight of uterus at PN 120 did not show changes in PBDE 99 treatment
groups, there was a significant decrease (p=0.007) in females exposed to Aroclor 10mg/kg
(fig. 4.19).
The relative uterus weight (fig. 4.20) in PBDE 99 exposed groups also was not affected,
while Aroclor 10mg/kg exhibited the same significant decrease (p=0.010).
Table 4.9: uterus weight (mean ± S.D).
Absolute weight Relative weight
Treatment Mean (g) S.D. Mean S.D. n
C 0.411 ±0.112 0.00167 ±0.000363 18
P1 0.429 ±0.0202 0.00188 ±0.0005 12
P10 0.424 ±0.239 0.00173 ±0.000558 10
Aro10 0.310* ±0.113 0.0013* ±0.00054 13
Aro30 0.247 ±0.125 0.00133 ±0.000466 6
* Different from control (p< 0.05)
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Figure 4.19: uterus absolute wet weight (g). Data represent mean ± S.D within every treatment group: Control
(C), PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30
mg/kg (Aro 30). Significant difference from control is shown by* (p<0.05).
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Figure 4.20: uterus relative wet weight (g). Uterus wet weights (g) was normalized to animal body weight (g).
Data represent means ± S.D within every treatment group: Control (C), PBDE 99 1 mg/kg (P1), PBDE 99 10
mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro 30). Significant difference from
control is shown by *(p<0.05).
Ovaries
The absolute weight of ovaries (fig. 4.21) did not show any significant change although the
highest PBDE 99 concentration seemed to increase the weight with a p value on the
borderline (p=0.053). Instead there were highly significant changes in relative weight (fig.
4.22). The P10 treatment group exhibited significant increase of relative weight (p=0.010),
the data indicate a dose-dependent increase but the change in the P1 group was not
significant. Aro 10 exposure also increased the relative weight (p=0.027).
Table 4.10: ovaries wet weight (mean ± S.D).
Absolute weight Relative weight
Treatment Mean (g) S.D. Mean S.D. n
C 0.113 ±0.0226 0.000459 ±0.000096 18
P1 0.113 ±0.0208 0.000500 ±0.000132 12
P10 0.135 ±0.0265 0.000558* ±0.000086 10
Aro10 0.125 ±0.0365 0.000544* ±0.00014 13
Aro30 0.089 ±0.0174 0.000466 ±0.000134 6
* Significant different from control (p<0.05)
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Figure 4.21: ovaries absolute wet weight (g). Data represent the mean ± S.D. of all wet weights within every
treatment group: Control (C) PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10)
and Aroclor 1254 30 mg/kg (Aro 30). Significant difference from control is shown by *(p<0.05).
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Figure 4.22: ovaries relative wet weight (g). Ovaries relative wet weights (g) were normalized to animal body
weight (g). Data represent means ± S.D within every treatment group: Control (C), PBDE 99 1 mg/kg (P1),
PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro 30). Significant
difference from control is shown by *(p<0.05).
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Liver
No significant changes were observed in absolute liver weight (fig. 4.23). A significant
increase of the relative weight was observed in females exposed to the higher dose of
PBDE99 (p=0.026) (fig. 4.24).
Table 4.11: liver wet weight (mean ± S.D.)
Absolute weight Relative weight
Treatment Mean (g) S.D. Mean S.D. n
C 7.14 ±0.540 0.02954 ±0.00348 18
P1 6.91 ±0.479 0.0303 ±0.00335 12
P10 7.98 ±1.355 0.0332* ±0.00551 10
Aro10 7.63 ±1.888 0.0332 ±0.00625 13
Aro30 6.41 ±2.048 0.0359 ±0.00817 6
* Significant different from control p<0.05
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Figure 4.23: liver absolute wet weight (g). Data represent the mean ± S.D within every treatment group: Control
(C), PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30
mg/kg (Aro 30).
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Figure 4.24: liver relative wet weight. Liver wet weight normalized with body weight. Data represent the mean ±
S.D. within every treatment group: Control (C), PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254
10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro 30). Significant difference from control is indicated by
a*(p<0.05).
Overview of organ weights in females:
A general overview of the effects of PBDE 99 and Aroclor 1254 on organ weight of adult
females offspring is given in the following schemes (scheme 4.3-4):
Absolute organ weight in female rat offspring:
P1 P10 Aro10 Aro30
Uterus
Ovaries
Liver
Scheme 4.3: absolute wet weight in females. Significant differences from control are shown by arrows. Their
numbers indicate the significant level compared to control. Blank cells show no significant changes.
Relative organ weight organ weight in female rat offspring:
P1 P10 Aro10 Aro30
Uterus
Ovaries
Liver
Scheme 4.4: relative organ wet weight in females. The organ weight was normalized to animal body weight.
Arrows show significant differences from control are. Their number indicates the significant levels compared to
control. Empty cells indicate no significant changes.
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4.6 mRNA Steady State Levels (Baseline)
The estrogen target gene mRNA levels were measured by real time-PCR in prostate,
ventral and dorsal lobe, and in uterus of the same experimental groups where organ
weights were determined (PN 120). In males, the genes studied were AR, ERα, ERβ and
IGF-1. In females PR, ERα, ERβ and IGF-1 were investigated. The mRNA amount
measured was normalized with Cyclophilin A (cyc) as reference gene. The number of
samples was 9 (n=9) for each treatment from different litters (the same number used for
organ weight determination). The Aroclor 30mg/kg samples were not analysed because of
the reduced group size due to increased postnatal mortality. The animals exposed to this
dose, in particular the females, hardly reached adulthood. Thus, changes in mRNA levels
in the 30 mg/kg Aroclor group might have been due to non-specific toxic effects. Data
represent the mean ± S.D.
4.6.1 Ventral Prostate
IGF-I
The Insulin-Like Growth Factor-I (IGF-I) mRNA level in ventral prostate was dose
dependently reduced I after PBDE 99 exposure with significant difference from Control in
both dose groups (p=0.01) in 1 mg/kg group, p=0.000 in 10 mg/kg (fig. 4.25). A significant
reduction was also present after Aroclor treatment (p=0.006).
Table 4.12: IGF-I mRNA levels in ventral prostate normalized to cyclophillin (mean±S.D.)
Treatments mean S.D. n
C 1.370 ±0.380 9
P1 0.979* ±0.248 8
P10 0.806* ±0.255 9
Aro10 0.917* ±0.200 8
* Significant different from control p<0.05
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Figure 4.25: IGF-I mRNA levels in ventral prostate. mRNA was quantified by Real Time-PCR and normalized
to cyclophilin. Data represent mean ± S.D within every treatment group: Control (C), PBDE 99 1 mg/kg (P1),
PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro 30). Significant
differences from control are shown by asterisks (*p<0.05, **p<0.01 and ***p<0.001).
Androgen Receptor
The Androgen Receptor (AR) mRNA level in ventral prostate lobe shows a massive
reduction in both PBDE 99 dosage groups (p=0.000) and was also decreased after Aroclor
exposure (p=0.006) (fig. 4.26).
Table 4.13: androgen receptor mRNA levels in ventral prostate (mean ± S.D.).
Treatments mean S.D. n
C 0.943 ±0.116 7
P1 0.169*** ±0.020 7
P10 0.189*** ±0.044 7
Aro10 0.731** ±0.172 8
* Significant different from control p<0.05, **p<0.01 and ***p<0.001
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Figure 4.26: androgen receptor mRNA levels. mRNA was quantified by Real Time-PCR and normalized to
cyclophilin. Data represent the mean ± S.D. Data represent mean ± S.D within every treatment group: Control
(C), PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30
mg/kg (Aro 30). Significant differences from control are shown by asterisks (*p<0.05, **p<0.01 and ***p<0.001).
Estrogen Receptor α
Estrogen receptor α mRNA was difficult to quantify; in the P10 treatment group, the level
of detection was 0.
Table 4.14: estrogen receptor α mRNA levels in ventral prostate (mean± S.D.).
Treatments mean S.D. n
C 0.051 ±0.019 7
P1 0.022 ±0.01 7
P10 0.000*** ±0.00 7
Aro10 0.029 ±0.0066 6
*** Significant different from control p< 0.001
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Figure 4.27: estrogen receptor α mRNA levels. mRNA was quantified by Real Time-PCR and normalized to
cyclophilin. Data represent mean ± S.D. within every treatment group: Control (C), PBDE 99 1 mg/kg (P1),
PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro 30). Significant
differences from control are shown by asterisks (***p< 0.001).
Estrogen Receptor β
The Estrogen Receptor β mRNA profile shows a significant decrease with a dose-
dependent pattern in the two PBDE99 dose groups(low dose a p=0.015, high dose
p=0.000). A significant decrease (p=0.021) was also found in the Aroclor group (fig. 4.28).
Table 4.15: estrogen receptor β mRNA levels in ventral prostate (mean± S.D.).
Treatments mean S.D. n
C 1.481 ±0.316 9
RESULTS
57
P1 0.978*** ±0.348 8
P10 0.080*** ±0.037 6
Aro10 1.011* ±0.366 9
* Significant different from control p<0.05, **p<0.01 and ***p<0.001
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Figure 4.28: estrogen receptor β mRNA in ventral prostate. mRNA was quantified by Real Time-PCR and
normalized to cyclophilin. Data represent mean ± S.D. within every treatment group: Control (C), PBDE 99 1
mg/kg (P1), PBDE 99 10 mg/kg (P10), Aroclor 1254 10 mg/kg (Aro 10) and Aroclor 1254 30 mg/kg (Aro 30).
Significant differences from control are shown by asterisks (*p<0.05, **p<0.01 and ***p<0.001).
4.6.2 Dorsal Prostate
IGF-I
IGF-I mRNA levels in dorsal prostate (fig. 4.29) were not affected by the exposure to
PBDE 99, whereas Aroclor induced a significant increase (p=0.000).
Table 4.16: IGF-I mRNA levels in dorsal prostate normalized to cyclophilin (mean± S.D.).
Treatments mean S.D. n
C 1.188 ±0.287 9
P1 0.975 ±0.185 9
P10 0.934 ±0.092 9
Aro10 2.250*** ±0.336 9
*** Significant difference from control p< 0.001
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Figure 4.29: IGF-I mRNA levels in dorsal prostate. mRNA was quantified by Real Time-PCR and normalized to
cyclophilin. Data represent mean ± S.D. within every treatment group: Control (C), PBDE 99 1 mg/kg (P1),
PBDE 99 10 mg/kg (P10), and Aroclor 1254 10 mg/kg (Aro 10). Significant differences from control are shown
by asterisks (***p<0.001).
Androgen Receptor
Androgen receptor mRNA expression in dorsal prostate (fig. 4.30) showed a dose-
dependent increase in response to PBDE 99 exposure with p=0.000 in both dosage
groups. Aroclor exposure did not affect AR mRNA levels.
Table 4.17: androgen receptor mRNA levels in dorsal prostate (mean± S.D.).
Treatments mean S.D. n
C 0.6507 ±0.103 9
P1 1.039*** ±0.17 8
P10 2.1048*** ±0.267 8
Aro10 0.481 ±0.1097 9
*** Significant difference from control p< 0.001
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Figure 4.30: androgen receptor mRNA levels in dorsal prostate. mRNA was quantified by Real Time-PCR and
normalized to cyclophilin . Data represent mean ± S.D. within every treatment group: Control (C), PBDE 99 1
mg/kg (P1), PBDE 99 10 mg/kg (P10), and Aroclor 1254 10 mg/kg (Aro 10). Significant differences from control
are shown by asterisks (***p<0.001).
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Estrogen Receptor α
Exposure to the high PBDE 99 dose (10 mg/kg) increased the level of ER  mRNA with
p=0.000. 1 mg/kg PBDE 99 and Aroclor did not significantly affect the ER  mRNA level
(fig. 4.31).
Table 4.18: estrogen receptor α mRNA levels in dorsal prostate (mean± S.D.).
Treatments mean S.D. n
C 0.727 ±0.183 7
P1 0.580 ±0.151 9
P10 1.278*** ±0.344 9
Aro10 0.610 ±0.168 8
***Significant difference from control (p< 0.001)
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Figure 4.31: estrogen receptor α mRNA levels in dorsal prostate. mRNA was quantified by Real Time-PCR and
normalized to cyclophilin. Data represent mean ± S.D. within every treatment group: Control (C), PBDE 99 1
mg/kg (P1), PBDE 99 10 mg/kg (P10), and Aroclor 1254 10 mg/kg (Aro 10). Significant differences from control
are shown by asterisks (***p<0.001).
Estrogen Receptor β
Both PBDE 99 doses decreased ER β mRNA levels in dorsal prostate (fig. 4.32), with p
value of 0.000. Aroclor was ineffective at the studied dose.
Table 4.19: estrogen receptor β mRNA normalized in dorsal prostate(mean± S.D.).
Treatments mean S.D. n
C 0.829 ±0.264 9
P1 0.430*** ±0.112 9
P10 0.422*** ±0.128 9
Aro10 1.057 ±0.146 7
***Significant difference from control (p< 0.001)
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Figure 4.32: estrogen receptor β mRNA levels in dorsal prostate. mRNA amount was quantified by Real Time-
PCR and normalized to cyclophilin. Data represent mean ± S.D. within every treatment group: Control (C),
PBDE 99 1 mg/kg (P1), PBDE 99 10 mg/kg (P10), and Aroclor 1254 10 mg/kg (Aro 10). Significant differences
from control are shown by asterisks (***p<0.001).
4.6.3 Uterus
IGF-I
The IGF-I mRNA level in uterus (fig. 4.33) did not exhibit any significant change after
PBDE 99 Aroclor 1254 exposure.
Table 4.21: IFG-I mRNA normalized in uterus (mean± S.D.).
Treatments mean S.D. n
C 0.177 ±0.065 11
P1 0.345 ±0.051 6
P10 0.219 ±0.093 6
Aro10 0.378 ±0.231 7
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Figure 4.33: IGF-I mRNA levels in uterus. mRNA was quantified by Real Time-PCR and normalized to
cyclophilin. Data represent mean ± S.D. within every treatment group: Control (C), PBDE 99 1 mg/kg (P1),
PBDE 99 10 mg/kg (P10), and Aroclor 1254 10 mg/kg (Aro 10).
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Progesterone Receptor
PBDE 99 treatment affected the PR mRNA level in uterus (fig. 4.34) by a significant dose
dependent decrease that reached statistical significance at both doses (low dose
treatment (P1) p=0.004, high dose (P10) p=0.01).
Table 4.21: progesterone receptor mRNA levels in uterus (mean± S.D.).
Treatments Average S.D. n
C 1.110 ±0.238 10
P1 0.833 ±0.400 8
P10 0.553 ±0.181 8
Aro10 0.842 ±0.439 9
*Significant difference from control (p<0.05), **(p<0.01)
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Figure 4. 34: progesterone receptor mRNA levels in uterus. mRNA was quantified by Real Time-PCR and
normalized to cyclophilin. Data represent mean ± S.D within every treatment group: Control (C), PBDE 99 1
mg/kg (P1), PBDE 99 10 mg/kg (P10), and Aroclor 1254 10 mg/kg (Aro 10). Significant differences from control
are shown by asterisks (*p<0.05, **<p<0.01).
Estrogen Receptor α
Estrogen receptor α m RNA levels were not significantly affected by exposure to PBDE99
or Aroclor 1254. The apparent increase in the low dose PBDE 99 dose group was not
significant.
Table 4.22: estrogen receptor α mRNA levels in uterus (mean± S.D.).
Treatments Average S.D. n
C 1.313 ±0.375 8
P1 1.855 ±0.566 9
P10 1.493 ±0.671 6
Aro10 0.7503 ±0.228 6
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Figure 4. 35: estrogen receptor  mRNA levels in uterus. mRNA was quantified by Real Time-PCR and
normalized to cyclophilin. Data represent mean ± S.D within every treatment group: Control (C), PBDE 99 1
mg/kg (P1), PBDE 99 10 mg/kg (P10), and Aroclor 1254 10 mg/kg (Aro 10).
Estrogen Receptor β
The effect of PBDE 99 on ER β mRNA levels was bell-shaped with an increase (p=0.000)
after 1 mg/kg and a decrease (p=0.005) after 10 mg/kg. In the Aro 10 treatment group the
level was 0.
Table 4.23: estrogen receptor β mRNA levels in uterus (mean± S.D.).
Treatments Average S.D. N
C 0.00293 ±0.00110 8
P1 0.00587*** ±0.00148 7
P10 0.00122** ±0.00025 6
Aro10 0.00000 ±0.00000 9
**Significant difference from control(p<0.01), ***(p<0.001)
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Figure 4.36: estrogen receptor β mRNA levels in uterus. mRNA was quantified by Real Time-PCR and
normalized to cyclophilin. Data represent mean ± S.D within every treatment group: Control (C), PBDE 99 1
mg/kg (P1), PBDE 99 10 mg/kg (P10), and Aroclor 1254 10 mg/kg (Aro 10). Significant differences from control
are shown by asterisks (**p<0.01 and ***p<0.001). Cases of no detection are indicated by N.D.
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General overview on mRNA expression levels
The following schemes give a general overview on effects of PBDE 99 and Aroclor 1254
on gene expression in ventral prostate, dorsal prostate and uterus:
Ventral Prostate:
P1 P10 Aro10
IGF-I   
AR   
ER   
ER   
Scheme 4.5: Ventral prostate mRNA expression. The arrows indicate significant changes. Their number is
proportional to the level of significance. Horizontal arrows indicate no significant change.
Dorsal Prostate:
P1 P10 Aro10
IGF-1   
AR   
ER   
ER   
Scheme 4.6: Dorsal prostate mRNA expression. The arrows indicate significant changes. Their number is
proportional to the level of significance. Horizontal arrows indicate no significant change.
Uterus:
P1 P10 Aro10
IGF-I   
PR   
ER   
ER   
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Scheme 4.7: Uterus mRNA expression. The arrows indicate significant changes. Their number is proportional to
the level of significance. Horizontal arrows indicate no significant change.
4.7. mRNA Levels after Acute Estrogen Challenge
This study was conducted to examine the sensitivity of estrogen target genes to estrogen
in adult developmentally chemical-exposed offspring. A single subcutaneous injection of
Estradiol (E2) (10g/kg of body weight) was given to adult gonadectomized male and
female offspring. After 6 hours, tissues were analysed.
In two separate experimental series, two different vehicles were used: Dimethylsufoxide
(DMSO) and olive oil in order to assess whether the acute effect of E2 depended on the
vehicle.
mRNA levels quantified by Real Time PCR were: IGF-1, AR, PR, ER and ER in ventral
prostate and uterus. Animals from every treatment group (C, P1, P10 and Aro10) were
gonadectomized at PN 70 and injected with E2 or with vehicle (DMSO or Olive-oil) on PN
84. The animal number per treatment group (vehicle or estradiol) was n=9-7 from 3
different litters per treatment in analyses with DMSO, in analyses with olive oil as vehicle
the litter number was: 8 for Control, 4 for PBDE 99 1 mg/kg, 6 for PBDE 99 10 mg/kg, and
7 for Aroclor 1254 10 mg/kg.
4.7.1 Acute Challenge Study with DMSO as Vehicle
The analyses were done on animals prenatally exposed to PBDE99 1 mg/kg body weight
and 10 mg/kg body weight and on controls, gonadectomized and injected with 10g/kg E2
in adulthood.
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I. mRNA levels in acute vehicle-injected gonadectomized rats of different treatment
groups
Ia Ventral Prostate
Ventral prostates of adult offspring gonadectomized at 10 weeks of age, sacrificed at week
12 and exposed to Vehicle (DMSO,) were analysed for their mRNA levels of IGF-I, AR,
ER and ER. Chemical-exposed, vehicle-injected groups were compared with untreated,
vehicle-injected controls. As compared to controls, a significant decrease in IGF-I mRNA
levels were observed in the PBDE 99 low dose group. The other genes were not
significantly different from gonadectomized controls (fig. 4.37). In intact offspring studied
under steady state conditions (fig. 4.25) the same tendency was observed in IGF-I and ER
 although there were no significant changes. ER mRNA levels were very low in both
intact and gonadectomized rats.
IGF-I mRNA in Ventral Prostate
AR mRNA in Ventral Prostate
B. AR mRNA in Ventral Prostate
IGF-I mRNA in Ventral Prostate
0
0.5
1
1.5
2
2.5
C+V P1+V P10+V
Treatments
m
R
N
A
no
rm
.
*
AR mRNA in Ventral Prostate
0
0.5
1
1.5
2
C+V P1+V P10+V
Treatments
m
R
N
A
no
rm
.
RESULTS
66
C. ER alpha in Ventral Prostate
ER mRNA in Ventral Prostate
ER mRNA in Ventral Prostate
Figure 4.37: mRNA levels in Ventral Prostate of gonadectomized acute vehicle-injected rat offspring. mRNA
amount was quantified by Real Time PCR and normalized to cyclophilin. Signicant differences are indicated by
asterisks one*(p<0.05), two** p<0.01) and three***(p<0.001).
Ib Uterus
Uteri from gonadectomized female offspring at week 10 and exposed to vehicle (DMSO)
at week 12, were analysed to determine the mRNA amount for IGF-I, PR, AR, ER and
ER. Significant differences as compared to vehicle-injected, gonadectomized controls
were observed in IGF-I P10 group, ER P10 group and in AR P1 group (fig. 36).
Comparing to the baseline levels there are not much similar tendencies.
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IGF-I mRNA levels in Uterus
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ER  levels mRNA in Uterus
AR mRNA levels in Uterus
Figure 4.38: mRNA levels in Uterus of gonadectomized acute vehicle-injected rat offspring. mRNA amount was
quantified by Real Time PCR and normalized to cyclophilin. Significant differences are indicated by asterisks
one*(p<0.05), two** p<0.01) and three***(p<0.001).
Acute effect of estradiol in different chronic treatment groups
For every chronic treatment group, the mRNA levels of individual genes in acutely E2-
injected rats were compared with those of rats injected with vehicle (fig.37). Levels were
expressed as 100% of the corresponding vehicle-injected group.
In males no significant estradiol-induced changes were observed except for AR in the
P10 group (fig.37) which was significantly reduced by acute administration of estradiol (p<
0.05). Thus, the P10 group exhibited a response to Estradiol that was not seen in controls.
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In females, the mRNA levels were significantly changed by E2 in almost all genes
investigated (fig. 4.40). IGF-I (fig. 4.40) showed significant increases in all groups exposed
to E2 compared to the vehicle group. PR (fig. 4.40) was significantly induced by E2 in P1
and P10, a similar tendency was also observed in controls. ER was down- regulated in
control and P1 groups (fig.4.39), with an analogous tendency in P10. The magnitude of the
effect of Estradiol appeared to be dose-dependently reduced in the PBDE-exposed groups
for IGF-I mRNA, and increased for ER mRNA. ER mRNA was quite difficult to detect by
Real Time PCR. A significant down-regulation by E2 was noted in the P10 (fig. 4.40). The
last gene investigated in uterus was AR (fig. 4.40) showing a down-regulation by E2 in the
various treatment groups.
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ER mRNA levels in Ventral Prostate after E2 injection
ER mRNA levels in Ventral Prostate after E2 injection
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Figure 4.39: mRNA expression after acute injection of estradiol (10g/kg s.c.) in ventral prostate of
gonadectomized offspring. mRNA amount is expressed as percentage of the corresponding vehicle-injected
control of the same chronic treatment group. DMSO was used as vehicle. mRNA levels for IGF-1, AR, ER and
ER were quantified by Real Time PCR and normalized to cyclophilin. Mean± S.D. Asterisk indicates p< 0.05
from corresponding vehicle-injected group.
 b. Uterus
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PR mRNA levels in Uterus after E2 injection
ER mRNA levels in Uterus after E2 injection
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ER mRNA levels in Uterus after E2 injection
AR mRNA levels in Uterus after E2 injection
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Figure 4.40: mRNA expression after acute injection of estradiol (10g/kg s.c.) in uterus of gonadectomized
offspring. mRNA amount is expressed as percentage of the corresponding vehicle-injected control of the same
chronic treatment group. DMSO was used as vehicle. mRNA levels for IGF-I, PR, ER and ER were quantified
by Real Time PCR and normalized to cyclophilin. Mean± S.D. One asterisk indicates p< 0.05, two p< 0.01 and
three p< 0.001 from corresponding vehicle-injected group.
4.7.2 Acute Estrogen Challenge Study with Olive Oil as Vehicle
The levels of estrogen target gene mRNAs after acute administration of E2 were also
investigated using another kind of vehicle, the Olive oil. E2 was first dissolved in ethanol
and then in sterileolive oil.
Olive oil with the same amount of ethanol was used as vehicle control. The genes
investigated were IGF-I, PR, AR, ER and ER in ventral prostate and uterus of Control,
PBDE 99 1 mg/kg, PBDE 99 10 mg/kg and Aroclor 1254 10mg/kg treatment groups.
I. mRNA levels in acute vehicle-injected rats of different treatment groups
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Ventral prostates of adult offspring gonadectomized at 10 weeks of age, sacrificed at week
12 and exposed to Vehicle (Olive oil,) were analysed for their mRNA levels of IGF-I, AR,
ER and ER.
A significant decrease, as compared to vehicle-injected controls was seen in IGF-1 mRNA
levels in the P10 dose group. The Aro 10 group exhibited a decrease in AR and an
increase in ER mRNAs (fig. 4.41). In intact offspring studied under steady state
conditions (fig. 4.25 and 4.28), the same tendency was seen in IGF-I and ER  although
there were no significant changes.
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ER mRNA levels in Ventral Prostate
Figure 4.41: mRNA expression after acute injection of estradiol (10g/kg s.c.) in ventral prostate of
gonadectomized offspring. Olive oil was used as vehicle. mRNA levels for IGF-I, AR, ER and ER were
quantified by Real Time PCR and normalized to cyclophilin. Data represent Mean± S.D. Asterisk indicates p<
0.05 from corresponding vehicle-injected group.
Ib Uterus
Uteri from gonadectomized female offspring at week 10 and exposed to vehicle (DMSO) at
week 12, were analysed to determine the mRNA amount for IGF-I, PR, AR, ER and ER.
Significant changes were observed in IGF-I for P1 group, PR was above vehicle-injected
controls in the Aro10 group, and ER in the P1 group (fig. 40). In the steady state series
there was similar tendency in IGF-I. ER in the P1 group, there was a similar increase.
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PR mRNA in Uterus
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Figure 4.42: mRNA levels in gonadectomized animals and exposed to Vehicle. Olive oil was used as vehicle. The
mRNA levels for IGF-I, PR, AR and ER were quantified by Real Time PCR and normalized to cyclophilin.
Data represent Mean± S.D. Asterisk indicates p< 0.05 illustrated with*, high significant changes (p<0.01) were
indicated with ** and extremely significant (p< 0.001) with ***.
Acute effects of estradiol in different treatment groups
mRNA levels of estradiol-injected and vehicle-injected, gonadectomized rats were
compared within every treated group, to see whether within the same group E2 influenced
the mRNA level in ventral prostate and in uterus. Effects were expressed as percent of the
vehicle-injected group to see eventual changes more clearly. In males, significant changes
were observed for IGF-I in the P10 group (fig.41) which was significantly induced by E2
(p< 0.05). ER was significantly elevated after E2 (p< 0.001) in P1 (fig.41).
In females, the mRNA levels were significantly altered in almost all genes investigated for
all treatment groups indicating high sensitivity to E2 stimulation (fig. 4.46). IGF-1 mRNA
was induced by E2 in all treatment groups (fig. 4.44). PR mRNA was stimulated in P1 and
Aro10. ER was down-regulated in P1 (fig.4.46). AR mRNA quantification was very
variable within the same treatment group which rendered analyses difficult. AR was
significantly down-regulated in the Aro 10 group.
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AR mRNA levels in Ventral Prostate after E2 injection
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ER mRNA levels in Ventral Prostate after E2 injection
Figure 4.43: mRNA expression after acute injection of estradiol (10g/kg s.c.) in ventral prostate of
gonadectomized offspring as percentage of the corresponding vehicle-injected control of the same chronic
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treatment group. Olive oil was used as vehicle. mRNA levels for IGF-I, AR, ER and ER were quantified by
Real Time PCR and normalized to cyclophilin. Mean± S.D. Asterisk indicates p< 0.05, two** p< 0.001 from
corresponding vehicle-injected group.
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ER mRNA levels in Uterus after E2 injection
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AR mRNA levels in Uterus after E2 injection
Figure 4.44: : mRNA expression after acute injection of estradiol (10g/kg s.c.) in uterus of gonadectomized
offspring. mRNA amount is expressed as percentage of the corresponding vehicle-injected control of the same
chronic treatment group. Olive oil was used as vehicle. mRNA levels for IGF-I, AR, ER and ER were
quantified by Real Time PCR and normalized to cyclophilin. Mean± S.D. One asterisk indicates p< 0.05, two p<
0.01 and three p< 0.001 from corresponding vehicle-injected group.
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5. Discussion
Polybrominated diphenylethers (PBDE) bioaccumulate which may influence the
developing organism. The PCB mixture, Aroclor 1254 was chosen as positive control
because of its structural similarity to PBDE 99. Depending on their structure, PCBs bind
either to the aryl hydrocarbon receptor (a receptor able to bind dioxin-like compounds) or
to estrogen receptors. Developmental effects of PCBs are known in experimental animals
and humans, but, the mechanism of action remains largely unsolved. Although PBDE 99
and Aroclor 1254 have the same structure they may have different effects. What is thought
to be common is their effects on thyroid and body weight, and neurotoxic effects after
perinatal exposure. No information on prenatal effects on developing neuro-endocrine
systems is currently available.
Prenatal exposure to PBDE 99 at the doses of 1mg/kg and 10 mg/kg supplied during
gestation days 10 to 18, did not alter the survival rate and the body weight in adult
offspring. These results suggest that PBDE99 does not exert a general toxic effect on
development, but a more subtile action. This points to the need to further investigations.
5.1 Classical toxicological endpoints: Organ weights
Males
PBDE 99 and Aroclor caused small but significant changes in reproductive organ weights
of adult offspring. This is relevant from the point of view of risk assessment, because it
clearly demonstrates an adverse effect of these chemicals.
The low dose PBDE 99 had effects on epididymis with a reduction of weight. Relative
weight was more affected. Most prominent is the increase in weight of the ventral and
dorsal prostate after PBDE 99 (significant for absolute or relative weight depending on
dose and tissue).
The dose-response relationship appeared to be bell shaped in ventral prostate, but normal
in the dorsal lobe. Increased prostate weight has been observed after developmental
exposure to estrogens or to the xenostrogen Bisphenol A (Saal et al., 1997; Nagel et al.,
1997); however, PBDE 99 exhibits only very little, estrogenic activity in vitro (Meerts et al.,
2001). Thus, the mechanism underlying the effect of PBDE on prostate weight remains
uncertain.
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Females
Adult uterine weight is not affected by prenatal PBDE 99 exposure with the two doses
used, suggesting a lower sensitivity of uterus to PBDE. Relevant decreases of the uterine
weight were observed in Aroclor 1254 exposed females.
It seems noteworthy that the PCB mixture, Aroclor, did not influence prostate weight. On
the other hand, uterine weight was affected by Aroclor, but not by PBDE 99. This indicates
differences in the effect patterns of PBDE and PCB.
The ovaries were not significantly affected when the absolute weight is considered, but
with normalization to body weight, a significant increase was demonstrated in high dose
PBDE 99 exposed females. An analogous effect was observed after 10 mg/kg Aroclor.
This increase could be due to a stimulation of follicular numbers in ovaries.
In contrast to males, relative liver weight was increased in PBDE 99 exposed females (10
mg/kg). Whether this change could be due to effects on liver metabolism remains to be
elucidated.
5.2 Gene expression in adult offspring under steady state conditions
Males
The gene expression analysis was carried out in males separately in ventral and dorsal
prostate, since the lobes have different regulation patterns. It could not be assumed that
PBDE 99 exposure would give the same effects in both lobes. Furthermore, the estrogen
target gene regulation in rat prostate is still not fully understood. The two estrogen
receptors (ER) undergo several changes in their expression in prostate gland during
development from the newborn to adult. This change results from interactions of many
factors (Ksano et al., 2003). External factors have the potential to interfere with some of
these crucial mediators and may lead to an alteration of the expression pattern. In this
case, we tested the capacity of compounds to exert a long-term effect.
Ventral Prostate
The genes investigated in ventral prostate showed several changes in their mRNA levels.
Both PBDE 99 doses affected the expression of mRNAs encoding for IGF-1, AR, ER and
ER.
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IGF-I mRNA was decreased by both PBDE doses and also by Aroclor. A very marked
decrease was detected in androgen receptor mRNA levels, where the reduction was
almost six fold compared to control ventral prostate for both dosages. The ER  mRNA
levels were reduced following a dose dependent manner. The ER  mRNA was difficult to
detect in high dose exposed animals.
Aroclor 1254, at the dose level used, also affected these genes in ventral prostate (fig.
5.1).
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Figure 5.1: overview of estrogen target gene mRNA levels in ventral prostate. The quantification of IGF-I, AR,
ER and ER was done by Real Time PCR. The mRNA amount was normalized to cyc. A.
Thus estrogen target genes in ventral prostate are affected by prenatal exposure to PBDE
99 and Aroclor 1254 in a significant way, with a general decrease in mRNA levels, though
the effect of the PCB mixture appear to be weaker than that of PBDE 99 (AR, ER ).
Several hypotheses could explain the mechanism by which PBDE down-regulates all the
genes investigated. Since the adult rat offspring were still exposed to PBDE 99, due to its
long half live, we cannot distinguish between effects resulting from prenatal exposure and
effects due to the presence of PBDE 99 in adulthood. If the effects were due to the
presence in the adult offspring, then PBDE 99 may inhibit the expression by antagonizing
the effects of agonist mediators for IGF-I, AR and ER , or alternatively by direct agonistic
action. Finally, effects might also be mediated indirectly, e.g., on ER regulating AR and
IGF-I. However, a reduction of ER would be expected to increase rather than decrease,
AR. In uterus, (Weihua et al. 2001), it was shown that when ER  was eliminated, (for
example in ER  knockout mice) AR was elevated, but in this case AR was decreased.
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Dorsal Prostate
Dorsal prostate was also affected by PBDE 99 and Aroclor 1254. While the IGF-I mRNA
expression was not altered by PBDE 99, the effect is different from what was observed in
ventral lobe. AR mRNA levels were increased in a dose-dependent way. ER  was not
changed in low dose exposure although the high dose elicited an increase by almost two
fold. In ventral lobe, ER  was hardly detectable in the low dose and undetectable in the
high dose group. ER  was down regulated to the same level by both PBDE 99 doses
similar to the ventral lobe.
Exposure to Aroclor 1254 resulted in a prominent increase in IGF-I mRNA levels; the other
genes did not seem to be altered by this compound (fig. 5.2). Again, the effect pattern was
different from ventral lobe and from PBDE 99.
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Figure 5.2: overview of estrogen target gene mRNA levels in dorsal prostate. The quantification of IGF-I, AR,
ER and ER was done by Real Time PCR. The mRNA amount was normalized to Cyc.
What comes out from these analyses is that PBDE 99 acts on rat prostate yielding
different effects in the two lobes. Possible explanations could be that PBDE 99 has the
same primary target but with opposite results due to different signalling mechanisms or
that it acts on different targets. Dorsal and ventral prostate have lobe-specific secretory
proteins, morphologic and functional differences (Hayward S.W. 2000) and may also have
different gene expression patterns.
The dose-dependent increase in expression of AR mRNA after PBDE 99 exposure could
be due to the decreased expression of ER , after 10 mg/kg combined with up-regulation
of ER . Such a mechanism would be compatible with the one proposed by Weihua: ER 
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appears to be a negative modulator of AR and acts to restrain the stimulatory action
mediated by ER  (Weihua et al., 2000).
Alternatively, the change in mRNA levels may result from developmental effects. An
increase in AR expression in mouse prostate linked with increased organ weight, has been
observed after prenatal exposure to elevated levels of estrogen (Saal et al., 1997).
The discrepancy of the effects of PBDE 99 on gene expression in the two prostate lobes
(strictly speaking three: ventral and dorsal + lateral) poses a problem for interpretation in
terms of mechanism. Moreover, possible actions of PBDE 99 are difficult to predict
because it is, at most, a very weak ER agonist (Meerts et al., 2001) which might exert
antagonizing actions as a partial agonist. Some differentiation between prostate lobes is
indicated by delayed effects of neonatal injection of estradiol. In adulthood, such rats
showed a slight increase of ER protein above control level in the lateral lobe (Prins et al.,
1997) which is included in the “dorsal lobe” tissue pieces, whereas, ER was reduced in
ventral prostate only (Prins et al., 1998) The balance between ER and ER may, in turn,
influence AR Expression.
Females
Uterus
Our results indicate changes in estrogen target gene mRNA levels in uterus of PBDE 99
exposed female rats. IGF-I mRNA level was not altered in a significant way in PBDE99
groups; this suggests that PBDE99 would not affect the rat uterine growth, as already seen
in uterine weight data. Marked changes were observed in PR mRNA levels where there
was a decline in a dose dependent manner (fig. 5.3).
ER  did not undergo significant changes. ER  mRNA exhibited a pronounced bell-
shaped dose response curve with up-regulation in low dose and down-regulation in high
dose exposed females (fig. 4). This response pattern does not appear to match that of
classical estrogenic effects. Neonatal exposure to DES or coumestrol was found to lead to
ER down-regulation, while the effect on ER is not clear (Medloch et al., 1988; Khurama
et al., 2000). Acute administration of ER agonists also down-regulates ER and ER
(Medloch et al., 1991); but, ER returns to normal levels upon prolonged exposure (Sato
et al., 1983). Uterine PR can be up- or down-regulated by estrogens depending on cell
type (Weihua et al., 2000; Kurita et al., 2001a, 2001b); but, no change in PR mRNA levels
was observed in our lab after prenatal DES exposure (Durrer, personal communication).
Thus, the PR mRNA effect also appears to represent an atypical response pattern.
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Figure 5.3: overview of estrogen target gene mRNA levels in uterus. The quantification of IGF-I, PR, ER and
ER was done by Real Time PCR. The mRNA amount was normalized to cyc.
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Figure 5.4: ER  mRNA level quantified by real time PCR in rat uterus. The mRNA amount was normalized to
cyc. and measured in C, P1, P10 and Aro10 animals.
In previous investigations it was found out that ER  is a positive modulator for PR, and
ER  is a negative modulator for ER  (Kurita et al., 2001)
Several mechanisms are being proposed, one is that ER  may form heterodimers with ER
 inhibiting its inductive property on PR (Weihua et al., 2000).
PBDE 99 given at a dose of 1 mg/ kg induced ER  mRNA expression, which might
explain the down regulation of PR. However, this explanation is not valid for the females
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exposed to 10 mg/kg of PBDE 99, PR was strongly down-regulated in the presence of a
marked down-regulation of ER and no change in ER mRNA.
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5.3. Acute Estrogen Challenge Study
Possible changes in the responsiveness of genes to estrogen were tested in 12 week old
animals gonadectomized and exposed to 10 µg/kg 17-Estradiol (E2), or to vehicle
(DMSO). Two weeks later the acute effect of E2 was then checked 6 hours after E2
exposure. Gonadectomy has often been used to better understand gene regulation and
the nature of action of estrogenic or anti-estrogenic compounds.
In males the response to E2 was analysed only in ventral prostate. Dorsal prostate is very
reduced in size and difficult to dissect reliably after gonadectomy.
Adult offspring out of different litters of the various groups, C, P1 and P10 were exposed to
E2 or vehicle (DMSO). Aroclor 1254 was not investigated because of insufficient number
of offspring.
The mRNA amounts measured in gonadectomized animals were also compared to those
measured in intact animals.
In gonadectomized males the mRNA levels in ventral prostate of treated groups did not
differ much from the gonadectomized control group. Significant changes were observed in
IGF-I, with a down-regulation in the P1 group, but levels were hold at the same level of the
control in the P10 group.
When the pattern was compared to that in intact animals, it became evident that the type
of effect of PBDE 99 differed:
AR and ER mRNA levels in ventral prostate where not affected in gonadectomized
animals in contrast to what was observed in intact offspring where there were marked
decreases in both PBDE 99 treatment groups (fig. 5.5). ER tended to decrease in
gonadectomized rats; but, the effect was not significant. In intact animals, there was a
more prominent decrease after both PBDE 99 doses (fig. 5.5).
IGF-I mRNA showed a decrease in ventral prostate of both gonadectomized and intact
animals, but in gonadectomized rats, the effect was restricted to the low dose group.
On the basis of these results, it is evident that the hormones produced by the testes and
their action on receptors in ventral prostate play an important part in the manifestation of
the PBDE effect pattern. The effect pattern appears to result from an interaction of (early
and/or late) effects of the chemical with the action steroid hormones. One possible
explanation would be that ER, ER and AR in ventral prostate have an increased
tendency to be down-regulated by circulating sex hormones.
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Figure 5.5: mRNA levels in ventral prostate of gonadectomized adult males (left) and intact adult animals
(right). Control, PBDE99 1 mg/kg/day or PBDE99 10 mg/kg/day. The gonadectomized animals were
injected with a Vehicle (DMSO). Quantification of IGF-I, AR, ER and ER mRNA by Real Time PCR.
mRNA amount of normalized to cyclophilin.
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In females, mRNA levels where altered in ovariectomized offspring. IGF-I showed a dose
dependent increase, ER showed an increase in PBDE 99 high dose group, and AR was
down regulated in the low dose group. PR and ER did not exhibit significant changes.
When we compare the mRNA levels of gonadectomized females to those of intact ones,
the effect patterns of PBDE 99 again differ in part, in analogy to males. ER differs
completely between gonadectomized and intact animals. IGF-I has in common an increase
in P1 group, but shows a bell-shaped dose-response in intact animals and a monotonic
one in gonadectomized males. A shift from monotonic to bell-shaped dose-response is
noted for PR mRNA. AR was not measured in baseline animals (fig. 5.6).
Thus, there also appear to exist an interaction of PBDE 99 with hormones secreted by the
ovaries.
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Acute response to estradiol in the various treatment groups
Males
Estrogen sensitivity of genes was assessed as percentage change in the various
treatment groups.
IGF-I mRNA levels in the control group, decreased in response to E2, as compared to the
control group injected with vehicle. In contrast, no change was detected in the P1 group. In
the P10 group, there was a slight estrogen-induced decrease (fig. 5.7).
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Figure 5.7: IGF-I mRNA
expression in ventral prostate of
gonadectomiezed rats. IGF-1
mRNA levels in vehicle (DMSO)
(V) and estradiol (E2) groups. Data
are expressed as % of the
respective vehicle-injected group of
the same treatment group.
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Figure 5.6: mRNA levels in uterus of gonadectomized adult females (left) and intact adult animals
(right). Control, PBDE99 I mg/kg/day or PBDE99 10 mg/kg/day. The gonadectomized animals were
injected with a Vehicle (DMSO). Quantification of IGF-I, PR, ER, ER AR mRNA by Real Time
PCR. mRNA amount of normalized to cyclophilin.
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AR mRNA, was down-regulated by the dose of E2 used (10 g/kg) only in P10
gonadectomized males, it might be that PBDE 99 enhances down-regulation of AR mRNA
by E2.
ER  and ER mRNA levels, were not significantly influenced by the acute E2 treatment.
Subtile effects may have been obscured by the comparatively high variability in the
groups. Thus, it was difficult to analyse estrogen sensitivity in this tissue in animals of the
present experimental series. A more extensive dose range of E2 would have been
necessary. The data with IGF-I suggest that low-dose exposure to PBDE 99 increased the
sensitivity of this gene to E2 in ventral prostate.
From these results it seems that males are not highly sensitive to exposure to 17-
estradiol.
In female uterus, the estrogen target gene mRNA levels exhibited marked changes 6
hours after E2 (10 g/kg).
An acute increase in IGF-I mRNA levels is in agreement with the known up-regulation of
this gene by estrogen (Norstedt et al., 1989; Klotz et al., 2000). If we compare each
estradiol group with the corresponding vehicle, we realize that induction is reduced in the
PBDE 99 exposed groups in a dose dependent manner (fig. 5.9).
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Figure 5.8: AR mRNA expression in
ventral prostate of gonadectomiezed
rats. AR mRNA levels in vehicle
(DMSO) (V) and estradiol (E2)
groups. Data are expressed as % of
the respective vehicle-injected group
of the same treatment group.
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Figure 5.9: IGF-I mRNA expression in
uterus of gonadectomized rats. IGF-I
mRNA levels in vehicle (DMSO) (V) and
estradiol (E2) groups. Data are expressed
as % of the respective vehicle-injected
group of the same treatment group.
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As mentioned above, PR in uterus can be up- or down-regulated by estrogen depending
upon tissue (Medlock et al., 1988; Khurama et al., 2000). It appears from the data in the
control group that the stimulatory effect dominated in our sample. The induction of PR
mRNA by E2 was enhanced in the PBDE 99-exposed rats in a dose dependent way (fig.
5.10).
The down-regulation of ER  mRNA levels (Medlock et al., 1999) in uterus was similar in
Control and PBDE 99-exposed groups.
In contrast, the repressive effect of E2 on uterine ER  mRNA levels appeared to be
dose-dependently enhanced in PBDE 99-exposed animals.
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Figure 5.10: PR mRNA expression
in uterus of gonadectomized rats.
PR mRNA levels in vehicle
(DMSO) (V) and estradiol (E2)
groups. Data are expressed as % of
the respective vehicle-injected
group of the same treatment group.
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Figure 5.10: ER  mRNA
expression in uterus of
gonadectomized rats. ER 
mRNA levels in vehicle (DMSO)
(V) and estradiol (E2) groups.
Data are expressed as % of the
respective vehicle-injected group
of the same treatment group.
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Figure 5.11: ER  mRNA expression in
uterus of gonadectomized rats. ER  mRNA
levels in vehicle (DMSO) (V) and estradiol
(E2) groups. Data are expressed as % of the
respective vehicle-injected group of the same
treatment group.
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AR mRNA levels are also down-regulated by E2 in uterus (Diel et al., 2000; Waters et al.,
2001). This effect was not markedly affected by PBDE 99 exposure.
Taken together, these data indicate gene-specific changes in estrogen sensitivity in uterus,
reduction with IGF-I and enhancement with PR and ER. In ventral prostate, the response
of IGF-I to E2 was also reduced by PBDE 99 (1 mg/kg).
Effect of Estradiol with olive oil as vehicle
Similar experiment was carried out on gonadectomized animals using olive oil as vehicle.
This experiment also included animals exposed to 10 mg/kg Aroclor 1254.
In ventral prostate of male controls, IGF-I mRNA levels were not altered by E2 injected in
olive oil (fig. 5.13). PBDE-exposed groups exhibited a tendency towards an increase of
levels after E2, but was not significant.
AR mRNA was not altered in controls. Levels in PBDE 99- and Aroclor-exposed groups
again tended to increase after estradiol injection; but, the change did not reach statistical
significance control (fig. 5.14).
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Figure 5.12: AR mRNA expression in
uterus of gonadectomized rats. AR
mRNA levels in vehicle (DMSO) (V) and
estradiol (E2) groups. Data are expressed
as % of the respective vehicle-injected
group of the same treatment group.
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Figure 5.13: IGF-I mRNA
expression in ventral prostate of
gonadectomized rats injected with
Vehicle (olive oil) or E2 in olive oil.
Data are expressed as % of the
respective vehicle group.
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ER  mRNA levels in ventral prostate were unaffected by E2 in controls, but increased by
E2 in both PBDE 99 groups with a significant difference from vehicle control after 1 mg/kg
in PBDE 99 (fig. 5.15).
ER  mRNA levels were not altered in Controls. The slight reduction by E2 in PBDE 99
treated animals was not significant (fig. 5.16).
In summary, there appeared to exist a difference between the effect of E2 in the case of
IGF-I mRNA which was down-regulated by E2 in DMSO, but not affected by E2 in olive oil
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Figure 5.14: AR mRNA expression in
ventral prostate of gonadectomized rats
injected with Vehicle (olive oil) or E2 in
olive oil. Data are expressed as % of the
respective vehicle group
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Figure 5.15: ER  mRNA expression in
ventral prostate of gonadectomized rats
injected with Vehicle (olive oil) or E2 in
olive oil. Data are expressed as % of the
respective vehicle group
Figure 5.16: ER  mRNA expression in
ventral prostate of gonadectomized rats
injected with Vehicle (olive oil) or E2 in
olive oil. Data are expressed as % of the
respective vehicle group
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injected in controls and for ER after PBDE 99. Since changes in the remaining mRNAs
did not reach statistical difference, a comparison of the two treatments is not possible.
In females, IGF-I, PR, ER and AR mRNAs were investigated in uterus. IGF-I mRNA
levels were increased much less in response to E2 in olive oil (300%) than in response to
E2 in DMSO (800%). Surprisingly, the induction by E2 was enhanced in PBDE 99-
exposed groups in comparison with the very low stimulatory level in controls. The effect
remained below the level reached in controls in the DMSO-experiment (600 vs 800%), and
hence, is difficult to interpret.
PR mRNA in uterus was induced by E2 injection similar to the experiment with DMSO.
Aroclor 1254-exposed rats also responded to E2. Apparent differences in the magnitude of
the response to E2 did not reach statistical significance (fig. 5.18).
Surprisingly ER  was not down-regulated by E2 (in olive oil) in controls. The P1 exhibited
down-regulation (similar to the DMSO experiment); whereas, the P10 group showed an
opposite effect (fig. 5.19).
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Figure 5.17: IGF-I mRNA expression in uterus
of gonadectomized rats injected with Vehicle
(olive oil) or E2 in olive oil. Data are expressed
as % of the respective vehicle group.
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Figure 5.18: PR mRNA expression in uterus of
gonadectomized rats injected with Vehicle (olive
oil) or E2 in olive oil. Data are expressed as %
of the respective vehicle group.
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AR mRNA levels were not significantly affected by E2 given in olive oil in controls and
PBDE 99-exposed groups (with exception of Aroclor exposed animals which exhibited
down-regulation) (fig. 5.20). A similar tendency was noticed in the P1 group.
These data again contrast with those of the DMSO experiment where a significant down-
regulation of AR mRNA levels was observed also in controls.
While the expected induction of IGF-I and PR could be demonstrated also with E2 given
in olive oil (though with a smaller effect in case of IGF-I mRNA), the failure to detect acute
down-regulation of ER and AR mRNA with E2 dissolved in olive oil renders this
experiment rather uncertain. The E2/DMSO data of controls fit better with data from the
literature. Thus, DMSO seems to be better suited as vehicle for this purpose at least with
respect to responses of the two organs studied. It is not clear what might be the difference
between the two vehicles. It is possible that absorption might be slower from the
subcutaneous olive oil depot. Since the acute response of the controls to E2 is difficult to
judge, the changes seem in PBDE 99- and Aroclor 1254- exposed animals remain
uncertain.
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Figure 5.19: ER  mRNA expression in uterus of
gonadectomized rats injected with Vehicle (olive
oil) or E2 in olive oil. Data are expressed as % of
the respective vehicle group.
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Figure 5.20: AR mRNA expression in uterus of
gonadectomized rats injected with Vehicle (olive oil)
or E2 in olive oil. Data are expressed as % of the
respective vehicle group.
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6. General discussion
Since PBDE 99 was identified in human samples as one of the main PBDE congeners, it is
important to understand its effects. Concern about PBDEs arose when it was realized that
concentrations started to rise exponentially, indicating a potential to be accumulated.
In contrast to the well-known PCBs mechanisms, the effects of PBDE are mostly unknown.
Our main focus was to investigate whether PBDE 99 has effects on development, whether
it acts on developing neuroendocrine systems, and whether the actions corresponded to
affect of endocrine disruptors.
In rat offspring exposed to PBDE 99 during development and studied under steady state
conditions, several changes in reproductive organ weights were detected in both sexes.
They were accompanied by changes in estrogen target gene expression patterns. This
means that PBDE 99 can affect developmental processes in reproductive organs. Since
the chemical was still present in adult offspring, it cannot be determined whether the
observed changes were a result of effects during early ontogeny or at later stages or, most
probably, of a combination of both. It is also important to note that the dose-response
relationship of PBDE 99 was not always monotonic, but in some cases appeared to be
bell-shaped, as far as can be judged from two doses. This phenomenon is often observed
with endocrine active chemicals. Finally, it is evident that the PCB mixture, Aroclor 1254,
caused a different effect pattern, in spite of structural similarities between PBDE and PCB.
The effect of PBDE 99 on the sensitivity of genes to estrogen was investigated in
gonadectomized animals in both sexes, using two different vehicles for estradiol (E2). The
study in female uterus appeared to be more responsive, 6 hours after of E2 injection than
ventral prostate of males. The study revealed tissue- and gene-specific changes in the
acute effect of estradiol on mRNA expression. Induction of IGF-I by estradiol was reduced
in PBDE 99-exposed adult offspring, both in uterus and ventral prostate. Effects of
estradiol on PR (induction) and ER (suppression) where enhanced in uterus. This
suggests to alterations in the regulation of estrogen target genes which again may be due
to actions of PBDE 99 during early ontogeny or at late stages, or a combination of both.
These effects are particularly difficult to discuss with PBDE 99 since its acute interaction
with endocrine mechanisms is not clear. As mentioned earlier, it displays only very little, if
any, estrogen agonist activity in vitro (Meerts et al., 2001) and is devoid of androgenic or
anti-androgenic in vitro activity (Lichtensteiger et al., 2003). In this respect, it was
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interesting to note that Gonadectomy markedly changed the mRNA expression pattern
which indicates that the manifestation of the PBDE 99 effect pattern is influenced by the
presence of circulating sex steroids.
We can conclude is that PBDE 99 interferes with the development of reproductive
organs. These actions characterize the substance as an endocrine disruptor.
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Abbreviations
AR: Androgen Receptor
Aro10: Aroclor 1254 10mg/kg
Aro30: Aroclor 1254 30mg/kg
BDE: brominated diphenyl ethers
DP: Dorsal Prostate
ERα: Estrogen Receptor α
ERβ: Estrogen Receptor β
GD: gestational day
IGF-I: Insulin Growth Factor I
N.D.: not detectable
PR: Progesteron Receptor
PBDEs: polybrominated diphenylethers
PBDE47: 2,2’,4,4’-tetrabromodiphenyl ether
PBDE99: 2,2’,4,4’,5-pentabromodiphenylether
PN: postnatal day
P1: PBDE 99 1mg/kg
P10: PBDE 99 10mg/kg
S.D.: standard deviation
VP: Ventral Prostate
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